

**GREGORY A. OTTERSON, M.D.**

B450 Starling Loving Hall, 320 W 10<sup>th</sup> Ave, Columbus, OH 43210  
614-293-9424 (Fax 293-7529)  
[Greg.Otterson@osumc.edu](mailto:Greg.Otterson@osumc.edu)

**Current Position**

Professor of Internal Medicine  
Division of Medical Oncology  
Department of Internal Medicine  
The Ohio State University

**Education**

1986-1989	Internship and Residency in Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois
1989-1992	Fellowship in Medical Oncology, Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland
1986 MD	Georgetown University School of Medicine, Washington, D.C. graduated <i>cum Laude</i>
1981 BA	Creighton University, Omaha, Nebraska (Theology), graduated <i>Summa cum Laude</i>

**Academic Appointments**

2009 - Present	Professor, Department of Internal Medicine, Ohio State University School of Medicine.
2004-2009	Associate Professor with Tenure, Department of Internal Medicine, Ohio State University, School of Medicine and Public Health.
1998-2004	Associate Professor, Department of Internal Medicine Ohio State University School of Medicine and Public Health
1994-1998	Assistant Professor, Department of Internal Medicine Uniformed Services University of the Health Sciences, Bethesda, Maryland

**Professional Positions and Experience**

2017 -	Associate Program Director, Division of Hematology/Oncology Fellowship Training Program
2016 - 2017	Interim Division Director, Division of Medical Oncology, Department of Internal Medicine, Ohio State University School of Medicine

2013 - 2016	Program Director, Division of Hematology/Oncology Fellowship Training Program
2008-2013	Associate Program Director, Division of Hematology/Oncology Fellowship Training Program
2007-2010	Interim Co-Director, Division of Hematology/Oncology, Department of Internal Medicine, Ohio State University School of Medicine
2006-2008	Fellowship Director, Division of Hematology/Oncology Fellowship Training Program
2003-2004	Interim Director, Division of Hematology/Oncology, Department of Internal Medicine, Ohio State University School of Medicine
2001-2010	Director, Solid Tumor Oncology Service, Division of Hematology/Oncology
1996-1998	Lieutenant Commander, Public Health Service Research Officer's Group National Institutes of Health
1992-1994	Instructor, Department of Internal Medicine Uniformed Services University of the Health Sciences, Bethesda, Maryland

### **Certification and Licensure**

1998-	Ohio State License Registration No. 74706
1989-1999	Maryland License Registration No. D38372
1986-1991	Illinois License Registration No. 076369
1991-present	ABIM/Subspecialty Board of Medical Oncology No. 124894
1989-	American Board of Internal Medicine No. 124894
1986	Diplomat of the National Board of Medical Examiners

### **Professional Memberships and Activities**

2002-	Fellow, American College of Physicians
1998-	Member, International Association for the Study of Lung Cancer
1998-	Member, Cancer And Leukemia Group B
1993-	Member, American Association for Cancer Research
1993-95, 1999-	Member, American Society of Clinical Oncology
1989-	Member, American Association for the Advancement of Science
1989-	Member, American College of Physicians
1983-1986	Member, American Medical Association, Medical Student Section
1982-1986	Member, American Medical Student Association

Grant Reviewer for the following:

- V Foundation
- Pelotonia Fellowship
- Pelotonia IDEA
- NCCN Oncology Research Program
- NCCN Affiliated Proposal
- Final Performance Reviews of Health Research Grants Department of Defense
- Lung Cancer Concept Awards 2012
- Lung Cancer Concept Awards, Association of Specialty Professors 2009
- Grant Proposal Reviewer, Panel B National Heart, Lung and Blood Institute 2002
- Ad Hoc Reviewer, Comprehensive Sickle Cell Center Program 2002
- Ad hoc Grant Proposal Reviewer Flight Attendant Medical Research Institute 2001

### **Editorial Board Appointments**

- Therapy Finder Advisors, Lung Cancer Editorial Board, CollabRx 2013-present
- Co-Editor, Advances in the Management of NSCLC: Highlights from the 2011 and 2012 ASCO
- Annual Meeting, ASCO Newsletter Pennsylvania Department of Health Cancer Institute
- Journal of the National Cancer Institute, Editorial Board. 2018
- Lung Cancer: Conference Highlights from the 2015 ASCO Annual Meeting

Journal Referee:

American Journal of Pathology  
Cell Growth and Differentiation  
Journal of Medical Genetics  
Journal of Clinical Oncology  
Cancer Commons: Lung, Assistant Editor  
Cancer Research  
International Journal of Cancer  
Journal of the National Cancer Institute  
Journal of Solid Tumors, Honorary Editor-in-Chief  
Oncogene  
Clinical Cancer Research

### **Committee Assignments and Administrative Services**

National/International Professional Organizations:

2008-2009	Task Force on Teaching and Applying Quality Principles Cancer and Leukemia Group B (now Alliance for Clinical Trials in Oncology Network)
2005-	Cadre Member, Respiratory Core Committee
2003-2005	Member, Respiratory Solid Tumor Correlative Sciences Committee
	Biotechnology and Biological Sciences Research Council – UK

National Comprehensive Cancer Network

- 2017 NCCN 22<sup>nd</sup> Annual Conference: 2017 General Poster Session  
Abstract Review Committee – Member
- 2015 NCCN Abstract Review Committee – 20<sup>th</sup> Annual Conference
- 2014 NCCN Foundation Young Investigator Award Review Committee
- 2014 Chair - NCCN NSCLC Panel – Webinar Series
- 2013–14 NCCN Abstract Review Committee – Member
- 2012-13 NCCN Abstract Review Committee - Member
- 2011 Member of Review Panel, Congressionally Directed Medical  
Research Program, Lung Cancer Research Program
- 2011-12 Chairman, NCCN BIBW2992 Request for Proposals Development  
Team - RFPDT (Oct. 21)
- 2010-2012 NCCN Lung Cancer Screening Panel Representative
- 2009 NCCN Temsirolimus RFA reviewer (Feb 19)
- 2002- NCCN Non-Small Cell Lung Cancer Panel Representative
- National Cancer Institute
- 2018 Ad Hoc reviewer, National Cancer Institute, Special Emphasis  
Panel, Small Cell Lung Cancer
- 2009 Theradex: University of California Davis CCC Audit Team (Feb  
17-18)
- 2005 Ad hoc Reviewer, Review Group –D
- 2004 Reviewer, Clustered Program Project Grants, June, 2004  
2003 Reviewer, Special Emphasis Panel ZCA1, Loan Repayment  
Program
- 1999 Lung Cancer Pathology Committee for Common Data Elements  
(CDEs)

University Service:

- 2016 - Graduate Medical Education Committee - Member
- 2016 - Fellowship Director Committee - Member
- 2016 - Internal Medicine Finance Committee - Member
- 2016 - Corporate Credentialing Committee - Member
- 2015 - 2017 Quality and Professional Affairs Committee – Member
- 2015 - 2017 Grievance Committee – Chair
- 2015 - Ethics Committee – Member
- 2014 - Pelotonia Fellowship Committee
- 2014 2014 Fall Intramural Research Program  
Clinical/Translational Science Review Session –  
Application Reviewer
- 2012- Member Promotion and Tenure Committee, OSU College  
of Medicine, Department of Internal Medicine
- 2012- Member, OSU Ethics Committee
- 2011 - Member, OSU P & T Committee
- 2011- Member, Data and Safety Monitoring Board (DSMB)
- 2011- Associate Division Director for Education, Division of  
Medical Oncology
- 2010- Member, OSUCCC Translational Therapeutics Program
- 2010- Member, Executive Clinical Management Team, James  
Cancer Hospital and Solove Research Institute

2010-2011	Member, Grievance & Appeals Committee, College of Medicine
2009-	Member and Reviewer, Pelotonia Fellowship Committee, James Cancer Hospital and Solove Research Institute
2009-	Member, Living with Lung Cancer Support Group, OSU CCC Jamescare for Life, Advisory Committee
2007	Member, Hematology/Oncology Division Director Search Committee, Department of Internal Medicine
2006-2009, 2017-	Member Promotion and Tenure Committee, OSU College of Medicine, Department of Internal Medicine
2005	Member, Department of Radiation Medicine Recruitment Committee
2005-	Member, Housestaff Selection Committee, Department of Internal Medicine
2005-2008	Member, Chemotherapy Administration Workgroup, James Cancer Hospital and Solove Research Institute
2004	Member, Project Cancer, Clinical Working Group, James Cancer Hospital and Solove Research Institute
2004	Member, Project Proton Working Group, James Cancer Hospital and Solove Research Institute
2003-2004	Member, Division of Dermatology Search Committee, Department of Internal Medicine
2003-2004	Member, Division of Radiation Oncology Search Committee, Department of Radiation Medicine
2003-	Member, Executive Committee, Clinical Scientific Review Committee, OSUCCC
2002-2010	Full Member, Molecular Biology and Human Cancer Genetics Program, OSUCCC
2002 -2005	Member, Housestaff Education Committee, Department of Internal Medicine
2002-2006, 2016-	Hematology/Oncology Training Liaison, Division of Hematology/Oncology, Department of Internal Medicine
2001-2003, 2015-	Member, James Cancer Hospital and Solove Research Institute Medical Staff Administrative Committee
2001-	Member, Finance Committee, Division of Hematology/Oncology
2000	Member, OSUCCC Associate Director for Administration Search Committee
2000-2002	Faculty Advisor, Ohio State University College of Medicine, Student Hematology-Oncology Interest Group
1999-2000	Member, Leadership Council for Clinical Value Enhancement, OSU Medical Center
1999-	Interviewer, Internal Medicine Residency Recruitment for Intern Applicants, Department of Internal Medicine,
1998-2002	Associate Member, Molecular Biology and Human Cancer Genetics Program, OSUCCC
1998	Member, Clinical Scientific Review Committee, OSUCCC

Institutional (non-OSU):

1983 Member, Committee on Introductory Clinical Science, Georgetown University School of Medicine

**Clinical Responsibilities**

1998- Attending Physician, Solid Tumor Oncology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

1998- Co-Director, Thoracic Oncology Program, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

1992-1998 Attending Physician, Solid Tumor Consult Service, National Naval Medical Center, Bethesda, MD

**Education Activities**

Teaching/Mentoring:

Faculty:

2017-present Dwight Owen, MD  
2017-present Carolyn Presley, MD  
2016 – Present Kai He, MD, PhD  
2011 – Present Erin Bertino, MD

Fellows:

2017-present Jean Bustamante-Alvarez, MD  
2017-present Natasha Jain, MD  
2016 – 2017 Dwight Owen, MD  
2015 – 2016 Kevin Koehler, MD  
2011-2014 Ben Chu, MD  
2008-2011 Erin Ort (Bertino), MD

Residents:

2015 – 2016 Kathleen Kerrigan, MD  
2015 – 2016 Jared Burkart, MD  
2015 – 2016 David Bond, MD

Graduate Students:

Doctoral Students (dissertation committee member)

- Kristine Kihm Browning, PhD, Dissertation Committee, The Graduate School of The Ohio State University, College of Nursing, Columbus, OH, "Smoking Behaviour after a Diagnosis of Lung Cancer," Defense Date: September 14, 2007. Advisor Mary Ellen Wewers, PhD.
- Romulo Martin Brena, PhD, Dissertation Committee, The Graduate School of The Ohio State University, Department of Molecular Genetics, Columbus, OH, "Aberrant DNA

- Methylation in Human Non-Small Cell Lung Cancer,” Defense Date: February 21, 2007. Advisor, Christoph Plass, PhD.
- Zunyan Dai, PhD, Dissertation Committee, The Graduate School of The Ohio State University, Department of Pathology, Columbus, OH, “Restriction Landmark Genomic Scanning to Identify Novel Methylated and Amplified DNA Sequences in Human Lung Cancer,” Defense Date: November 6, 2002. Advisor, Christoph Plass, PhD.
  - Amy B Coxon, PhD, Dissertation Research Committee, Columbian School of Arts and Sciences of The George Washington University, Department of Genetics, Washington, DC, “A Mouse Model for Neuroendocrine Tumorigenesis,” Defense Date: March 7, 2000. Advisor, Frederic J Kaye, MD.

Doctoral Students (general examination committee member)

- Colin T Walsh, Graduate Research Associate, Division of Pharmaceutics, College of Pharmacy, The Ohio State University. October 17, 2003. Advisor, Jessie L-S Au, PharmD, PhD.
- Sarah H. Tannehill-Gregg, Graduate Research Associate, Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University. September 12, 2000. Advisor, Thomas J. Rosol, DVM, PhD.

Teaching Responsibilities:

- 2007 Course organizer and speaker, Ohio State University Center for Continuing Medical Education, 21<sup>st</sup> Century Care for Lung Cancer, Inhalational therapies for lung cancer, March 2-3, 2007.
- 2003 Course Director, “Rushing Against Thoracic Tumors; Innovative Therapies in Thoracic Malignancies.” Continuing Medical Education Course, OSU Center for Continuing Medical Education, September 12-13, 2003.
- 2001-2003 Facilitator, Problem Based Learning Pathway, The Ohio State University College of Medicine and Public Health
- 2000-2002 Coordinator, CCC Medical Grand Rounds, OSU
- 1999 Introductory Clinical Medicine, General Clerkship, OSU
- 1998-2000 Weekly attendance at Clinical Review Conference, Division of Hematology/Oncology, OSU Department of Internal Medicine

Lectures for Trainees:

1. Human Cancer Genetics Seminar. Molecular basis for incomplete penetrance of retinoblastoma, February, 1999.
2. Department of Internal Medicine, Noon Housestaff Lecture, Molecular Oncology, October 6, 1999.

3. Department of Internal Medicine, Morning Report, March 22, June 7, August 25, September 21, December 6, 2000, April 2, 2001, September 8, November 16, December 14, 2004, February 22, March 15, May 3, October 5, December 13, 2005, September 21, 2006, January 12, 2007, March 18, 2010.
4. Department of Internal Medicine, Resident's core competency lecture series, Lung Cancer, September 15, 2000, August 1, 2003, March 6, 2007, May 27, 2008, April 6, 2010.
5. Division of Hematology/Oncology, Fellows Lecture, Lung Cancer Biology and Genetics, October 30, 2000, March 30, 2004, October 7, 2005, May 20, 2008
6. Department of Internal Medicine, Med 3 lecture series, Oncologic Emergencies, February 21, April 18, August 15, 2002, April 17, 2003.
7. Department of Otolaryngology, Basic Principles of Head and Neck Oncology Course, Lung Cancer, September 7, 2002, August 23, 2003, August 28, 2004, August 20, 2005, August 16, 2006, August 16, 2007.
8. Division of Hematology/Oncology, Fellows Lecture, Unusual Thoracic Tumors, November 26, 2002.
9. Division of Hematology/Oncology, Fellows Lecture, Small Cell Lung Cancer, April 6, 2004, October 4, 2005, May 13, 2008, November 24, 2009.
10. Department of Internal Medicine, Resident's core competency lecture series, Complications of Cancer Therapy, November 2, 2004.
11. Division of Pulmonary and Critical Care Medicine Fellows Lecture: Lung Cancer, August 5, 2005.
12. Division of Pulmonary and Critical Care Medicine Grand Rounds: Lung Cancer, October 14, 2005.
13. Division of Hematology and Medical Oncology, Fellows Lecture Team Lead Seminar, "Role of the Fellow: Training in Hematology/Oncology Patient Care and Research", August 12, 2010.
14. Division of Hematology and Medical Oncology, Fellows Lecture Job Search Seminar, "Tips for Recruitment and Securing an Interview and Faculty Position: What We Look for in Physicians Completing Fellowship Searching for Academic Faculty Positions", August 18, 2010.
15. Division of Hematology and Medical Oncology, Fellows Lecture, "Non-small cell lung cancer-advanced", October 18, 2011.
16. Division of Hematology and Medical Oncology, Fellows Lecture, "Small Cell Lung Cancer", November 1, 2011.



Laboratory Students:

<u>Name</u>	<u>Position</u>	<u>Years</u>	<u>Field of Study</u>
Li Wang, MD	Postdoctoral	2006-2008	DNA Methylation/Epigenetics
Xin Wu, PhD	Postdoctoral	2004-	DNA Methylation/Epigenetics
Matthew Beal, BS	Summer Intern	2000, 2001	DNA Methylation/Histone Acetylation, affect of acetylation on p53 function
Wei-Guo Zhu, PhD	Postdoctoral	1999-2003	DNA Methylation/Histone Acetylation <i>(currently Professor in Department of Biochemistry and Molecular Biology, Peking University Health Sciences Center, Beijing, China)</i>
Kari Nguyen, BS	Summer Intern	1997-1998	Low Penetrance Retinoblastoma
Wieslawa Niklinska, PhD	Postdoctoral	1996-1997	Genetic Changes in Lung Cancer <i>(currently Professor in Department of Histology, Bialystok Medical University, Bialystok, Poland)</i>
Lisa Pogoda	Summer Intern	1995	Low Penetrance Retinoblastoma

Student Awards to Otterson Trainees:

Erin Bertino, MD	2009 AACR/ASCO Workshop: Methods in Clinical Cancer Research (Vail Workshop)
Matthew Beal, BS	2001 Landacre Day Student Research Forum Oral Abstract Presentation, OSU
Adam Pleister, MD	Outstanding Poster Presentation at 11 <sup>th</sup> World Conference on Lung Cancer, Barcelona, Spain, 2005.

Clinical Trainees:

<u>Name</u>	<u>Position</u>	<u>Years</u>	<u>Current Position</u>
Mary McCoullough, MD	Clinical Fellow	1998-2001	Private Practice, Cincinnati, OH
Andrew Grainger, MD	Clinical Fellow	2001-2003	Private Practice, Columbus, OH
Kavitha Kosuri, DO	Clinical Fellow	2003-2006	Medical Oncologist, St. Louis Cancer & Breast Institute.
Matthew Karpenko, MD	Clinical Fellow	2006-2008	Private Practice, Florida
Erin Bertino (Ort), MD	Clinical Fellow	2008-2011	Assistant Professor, OSU
Benjamin Chu, MD	Clinical Fellow	2011-2014	Assistant Professor, University of Connecticut, Hartford Hospital
Justin Klamerus, MD	Medical Resident	2004-07	President, Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan
Adam Pleister, MD	Medical Resident	2004-06	Assistant Professor, OSU
Steven McCormack, MD	Medical Resident	2006-08	Clinical Assistant Professor, University of Minnesota

Erin Ort (Bertino), MD    Medical Resident    2005-08    Assistant Professor,  
Medical Onc., OSU

## Honors and Awards

### National

2011-2015    Elected, "Best Doctors in America"  
2002    Election as Fellow, American College of Physicians  
1996-1999    Selection as NIH LRP (Loan Repayment Program)  
recipient  
1983    Viets Fellowship (Myasthenia Gravis Foundation)  
1983    *Alpha Omega Alpha* election  
1980    *Alpha Sigma Nu* election  
1977-1981    National Merit Scholarship

### Institutional/Local

2007    Best Lung Cancer Doctor in Columbus, Columbus  
Dispatch "Docs Rate Docs" survey  
2006    Bertha Bouroncle Teaching Award, OSU Division of  
Hematology/Oncology (elected by Division Fellows)  
2003    Award of Excellence in LIVE CME Webcast Presentation,  
OSU Center for CME  
2000    OMEN-TV "Best Team" Award, 1999-2000 series.  
1986    Biochemistry Academic Award, Georgetown University School of  
Medicine  
1986    Graduated *cum Laude*  
1981    Graduated *Summa cum Laude*  
1977-1981    Honors Program, Creighton University  
1977-1981    Presidential Scholarship, Creighton University

## Grants and Contract Awards

### Current

2014-present    NIH/NCI 5U10CA180850-04  
Title: OSU as Network Lead Academic Participating Site  
for the NCI NCTN  
PI: Clara D. Bloomfield, MD  
Co-I: Gregory A. Otterson  
\$1,311,684

9/9/2009 – present    NIH 1K12CA133250-01  
Title: Translational Training Grant in Experimental Therapeutics  
PI: John C. Byrd, MD  
Co-I: Gregory A. Otterson, MD  
\$5,008,928 total multiyear direct costs

- 2012-present                    NIH T32 1T32CA136422-01A1  
Training Clinical Investigators in Hematology/Oncology  
PI: Steven Clinton, MD, PhD  
Co-I: Gregory Otterson, MD  
\$1,093,609 total multiyear direct costs
- Completed:
- 07/01/03-12/31/16            American Cancer Society, Ohio Division  
Ohio State University Institutional Research Grant  
PI: Gregory A. Otterson, MD  
\$120,000/yr
- 04/01/98-03/31/15            NIH/NCI 5 U10 CA77658-07  
Title: CALGB - The Ohio State University  
PI: Clara D. Bloomfield, MD  
Co-I: Gregory A. Otterson, MD  
\$2,653,113 (D)
- 04/15/98-2/28/13             NIH 3UM1CA186712-03S2  
Title: Phase I Trials of Anti-Cancer Agents  
PI: Michael Grever, MD  
Co-I: Gregory A. Otterson, MD  
\$241,958
- 9/1/2008 – 8/31/2010        NIH/NCI 1R21CA121582-01A1 (NCE)  
Title: MR-Predictive Assay in Pre-Operative Lung Cancer  
Therapy: Response/Resectability  
PI: John C. Grecula, MD  
Co-PI: Gregory A. Otterson, MD  
\$500,000 total multiyear direct costs
- 1/1/2006 – 12/31/2009        NIH N01-CM-62207  
Early Therapeutics with Phase II Emphasis  
PI: Miguel Villalona-Calero, MD,  
Co-PI: Gregory A. Otterson, MD  
\$3,041,729 (project multiyear direct costs)
- 09/21/08-09/21/10            NCCN (NCE)  
Title: Phase II Trial of Abraxane plus Carboplatin for Advanced  
NSCLC for Patients at Risk of Bleeding from VEGF Directed  
Therapies  
PI: Gregory A. Otterson, MD  
\$300,000
- 10/1/2009-9/30/11            NIH 1 RC2 CA148302-01  
Loss of miR-29s as predictor of response to demethylating agents  
PI: Carlo Croce, MD  
Co-PI: Gregory A. Otterson, John Byrd, Guido Marcucci

\$2,732,574 total multiyear costs

2/14/13 – 2/13/15

Mayo Foundation  
Study Title: Ph2 NTX-010 Replication- Picornavirus  
Platinum-Containing Cytoreductive Induction Chemo Pts  
W/ SCLC  
Study Number: NCCTG-N0923  
Budget: Total anticipated budget: \$ 2,780.00

10/29/03-12/31/08

Ohio Department of Development  
Comprehensive Program for the Prevention, Detection and  
Treatment of Lung Cancer  
PI: Michael Caligiuri, MD  
Project PI: Gregory A. Otterson, MD  
\$608,848 (subproject multiyear costs)

1/1/2006 – 10/6/2006

Women Against Lung Cancer  
Epigenetic contributions to gender-specific differences in lung  
cancer  
P.I. Christoph Plass, PhD  
\$50,000

01/01/05-12/31/06

Mesothelioma Applied Research Foundation  
Title: Epigenetic Changes in Mesothelioma  
PI Gregory A. Otterson, MD  
\$50,000/yr

07/01/03-12/31/06

Zivena, Inc.  
Title: A phase I/II study of inhaled doxorubicin plus IV docetaxel  
and cisplatin in patients with locally advanced or metastatic  
unresectable non-small cell lung cancer.  
PI Gregory A. Otterson, MD  
\$126,500

10/01/02-9/30/05

V-Foundation Translational Research Award  
Title: Aberrant DNA methylation as a target for chemoprevention/  
chemotherapy in lung cancer.  
PI: Christoph Plass, PhD, Co-PIs, Gregory A. Otterson, MD, Ming  
You, MD, PhD  
\$200,000/yr

05/15/02-03/31/05

NIH R21 CA92958-01A1  
Title: Preoperative treatment of lung cancer with rhuMAb VEGF  
PI: Gregory A. Otterson, MD  
\$222,500

03/15/00-03/15/04

Battelle Pulmonary Therapeutics  
Title: A phase I and clinical pharmacologic study of inhaled  
doxorubicin in adults with advanced solid tumors affecting the  
lungs.

	PI Gregory A. Otterson, MD \$126,500
11/01/98-11/01/99	Order of the Eastern Star, Grand Chapter of Ohio Title: Restriction Landmark Genomic Scanning in Lung Cancer PI: Gregory A. Otterson, MD \$9,800
11/01/98-1/31/01	American Cancer Society, Ohio Division, Inc. Title: Methylation and Acetylation in Lung Cancer PI Gregory A. Otterson, MD \$20,000
07/01/99-09/30/01	Ohio Cancer Research Associates Title: Molecular Changes in Nonsmall Cell Lung Cancer PI Gregory A. Otterson, MD \$46,000 (total direct)
07/17/01-06/01/03	Enzon, Inc. Title: A phase II study of PEG-camptothecin in patients with small cell lung cancer PI Gregory A. Otterson, MD \$18,200
09/19/01-08/31/03	NIH R21 CA91547-01A1 Title: Suramin to enhance paclitaxel and carboplatin in NSCLC PI: Jessie Au, PhD \$250,000
09/01/99-08/31/00	Core Facility Award, The Ohio State University Comprehensive Cancer Center Title: A screening strategy for discovery of hypomethylating chemotherapeutic agents. PI Gregory A. Otterson, MD \$12,500
11/29/99-09/30/01	Warner-Lambert Company Title: A randomized double-blind placebo controlled multicenter study of CI-994 capsules plus gemcitabine infusion versus placebo capsules plus gemcitabine infusion as a second line treatment in patients with advanced non-small cell lung cancer 994-013 PI Gregory A. Otterson, MD \$58,500

### **Clinical Trials/Protocols**

Institutional and NCI-Sponsored Cooperative Group Protocols:

- 2010 NCI #8695 Enhancement of Cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with Lenalidomide (CC-5013) in Advanced Solid Tumors: A Phase I/IB study
- 2010 NCI #8617 Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients with Advanced NSCLC
- 2008 OSU 08059 Phase II Trial of Abraxane plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding from VEGF Directed Therapies  
Principal Investigator
- 2007 CALGB 30602 A phase II study of dasatinib (NSC 732517, IND 73969) in patients with chemosensitive relapsed small cell lung cancer  
National Study Co-Chair
- 2003 CALGB 30304 A phase II study of single agent depsipeptide (FK228) (NSC 630176; IND 51,810) in relapsed small cell lung cancer  
National Study Chairperson
- 2003 NCI #6237 A Phase I study of Decitabine in combination with valproic acid in patients with non-small cell lung cancer  
Principal Investigator
- 2002 OSU #0251 Phase I-II study of Doxorubicin (Doxorubicin HCl inhalation solution, Resmycin) plus IV docetaxel and cisplatin in patients with locally advanced or metastatic unresectable non-small cell lung cancer  
National Study Chairperson
- 2001 NCI #2655 A phase 2 study of neoadjuvant rhumab VEGF (bevacizumab) in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer.  
Principal Investigator
- 2000 NCI # 2530 A phase I study of fenretinide combined with paclitaxel and cisplatin for the treatment of refractory solid tumors  
Principal Investigator
- 1999 OSU 9987: Phase I/II Study of G3139, a bcl-2 antisense oligonucleotide, combined with paclitaxel for the treatment of recurrent small cell lung cancer.  
Institutional Study Chairperson
- 1999 OSU 9984: A phase II study of Oxaliplatin in combination with Paclitaxel in non-small cell lung cancer.  
Institutional Study Chairperson

- |      |  |
|------|--|
| 2000 | OSU 9985: Phase I and clinical pharmacologic study of inhaled Doxorubicin in adults with advanced solid tumors affecting the lungs.<br>Study Chairperson |
| 1998 | CALGB 39807: Capecitabine (Xeloda) in malignant mesothelioma: a phase II study.<br>National Study Chairperson  |

## Publications

1. Koethe SM, Dupont BL, Calvo AM, **Otterson G**, McQuillen MP. (1987). Anti-acetylcholine receptor antibodies in myasthenia gravis: binding to membrane-bound *Torpedo* AChR. Ann N Y Acad Sci 505:557-65.
2. **Otterson G**, Lin A, Kaye F. (1992). Genetic etiology of lung cancer. Oncology 6:97-107.
3. Kratzke RA, **Otterson GA**, Lin AY, Shimizu E, Alexandrova N, Zajac-Kaye M, Horowitz JM, Kaye FJ. (1992). Functional analysis at the Cys<sup>706</sup> residue of the retinoblastoma protein. J Biol Chem 267:25998-26003.
4. **Otterson GA**, Kratzke RA, Lin AY, Kaye FJ. (1993). Alternative splicing of the *RBP1* gene clusters in an internal exon that encodes potential phosphorylation sites. Oncogene 8:949-57.
5. Kratzke RA, Shimizu E, Geradts J, Gerster JL, Segal S, **Otterson GA**, Kaye FJ. (1993). RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. Cell Grow & Diff 4:629-35.
6. Savarese DMF, Denicoff AM, Berg SL, Hillig M, Baker SP, O'Shaughnessy JA, Chow C, **Otterson GA**, Balis FM, Poplack DG, Cowan KH. (1993). Phase I study of high-dose Piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol 11:1795-1803.
7. **Otterson GA**, Flynn GC, Kratzke RA, Coxon A, Johnston PG, Kaye FJ. (1994) *Stch* encodes the "ATPase core" of a microsomal stress70 protein. EMBO J 13:1216-25.
8. Kratzke RA, **Otterson GA**, Hogg A, Coxon AB, Geradts J, Cowell JK, Kaye FJ. Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. Oncogene 9:1321-6.
9. Shimizu E, Coxon A, **Otterson GA**, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson B, Mulshine JL, Minna JD, Gazdar AF, Kaye FJ. (1994). RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9:2441-8.

10. **Otterson GA**, Kratzke RA, Coxon A, Kim YW, Kaye FJ. (1994) Absence of p16<sup>INK4</sup> protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9:3375-8.
11. Kim YW, **Otterson GA**, Kratzke RA, Coxon AB, Kaye FJ. (1994) Differential specificity for binding of Retinoblastoma Binding Protein 2 to RB, p107, and TATA-Binding Protein. Mol Cell Biol 14:7256-64.
12. Kelley MJ, **Otterson GA**, Kaye FJ, Popescu NC, Johnson BE, DiPaolo JA. (1995) *CDKN2* in HPV-positive and HPV-negative cervical carcinoma cell lines. Int J Cancer 63:226-30.
13. Brodsky G, **Otterson GA**, Parry BB, Hart I, Patterson D, Kaye FJ. (1995) Localization of *Stch* to human chromosome 21q11.1. Genomics 30:627-8.
14. Alexandrova N, Niklinski J, Bliskovsky V, **Otterson GA**, Blake M, Kaye FJ, Zajac-Kaye M. (1995) The N-terminal domain c-Myc associates with  $\alpha$ -tubulin and microtubules *in vivo* and *in vitro*. Mol Cell Biol 15:5188-95.
15. Kratzke RA, **Otterson GA**, Lincoln CE, Ewing S, Geradts J, Kaye FJ. (1995) Absence of the p16<sup>INK4</sup> cyclin dependent kinase inhibitor in primary mesothelioma tumors. JNCI 87:1870-75.
16. **Otterson GA**, Khleif SN, Chen W, Coxon AB, Kaye FJ. (1995) *CDKN2* gene silencing in lung cancer by DNA hypermethylation and kinetics of p16<sup>INK4</sup> protein induction by 5-aza 2'deoxyctidine. Oncogene 11:1211-16.
17. Khleif SN, Degregori J, Yee CL, **Otterson GA**, Kaye FJ, Nevins JR, Howley PM. (1996) Inhibition of cyclin D:CDK4/CDK6 activity is associated with an E2F1-mediated induction of CDKI activity. Proc Natl Acad Sci USA 93: 4350-4354.
18. **Otterson GA**, Monahan BP, Harold N, Steinberg S, Frame JN, Kaye FJ. (1996) Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 101:406-412.
19. Chen W, **Otterson GA**, Lipkowitz S, Khleif SN, Coxon AB, Kaye FJ. (1997) Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene 14:1243-1248.
20. **Otterson GA**, Chen W, Coxon AB, Khleif SN, Kaye FJ. (1997) Incomplete penetrance of familial retinoblastoma linked to germline mutations that result in partial loss of RB function. Proc Natl Acad Sci USA 94:12036-12040.
21. **Otterson GA**, Kaye FJ. (1997) A "core ATPase", HSP70-like structure is conserved in human, rat, and *C. elegans* STCH proteins. Gene 199(1-2): 287-292.
22. Sellers WR, Novitch BG, Miyake S, Heith A, **Otterson GA**, Kaye FJ, Lassar AB, Kaelin WG. (1998) Stable binding to E2F is not required for the retinoblastoma



- protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes and Development 12:95-106.
23. **Otterson GA**, Xiao G-H, Geradts J, Jin F, Chen W, Niklinska W, Kaye FJ, Yeung RS. (1998) Protein expression and functional analysis of the *FHIT* gene in human tumor cells. JNCI 90:426-432.
  24. Coxon AB, Ward JM, Geradts J, **Otterson GA**, Zajac-Kaye M, Kaye FJ. (1998) RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer. Oncogene 17:1625-1628.
  25. **Otterson GA**, Nguyen K, Coxon A.B, Modi S, Kaye FJ. (1999) Temperature sensitive *RB* mutations linked to incomplete penetrance of familial retinoblastoma in 12 families. Am J Hum Genet 65:1040-1046.
  26. McGinn CJ, Pestalozzi BC, Drake JC, Glennon MC, Kunugi K, **Otterson G**, Allegra CJ, Johnston PG, Kinsella TJ. (2000) Cell cycle regulation of the G0/G1 transition in 5-fluorouracil sensitive and –resistant human colon cancer cell lines. Cancer J, 6:234-242.
  27. Zhu W-G, Lakshmanan RR, Beal MD, **Otterson GA**. (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res, 61:1327-1333. PMID: 11245429
  28. Dai Z, Lakshmanan RR, Zhu W-G, Smiraglia DJ, Rush LJ, Frühwald MC, Brena RM, Li B, Wright FA, Ross P, **Otterson GA**, Plass C. (2001) Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia, 3:314-323. PMID: 11571631
  29. Zhu W-G, Dai Z, Ding H, Srinivasan K, Lakshmanan RR, Hall J, Villalona-Calero MA, Plass C, **Otterson GA**. (2001) Increased expression of unmethylated CDKN2D by 5-aza, 2'deoxyctidine in human lung cancer cells. Oncogene, 20:7787-7796. PMID: 11753657
  30. Rudin CM, **Otterson GA**, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE. (2002) A pilot trial of G3139, a *bcl-2* antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Annals of Oncology, 13:539-545. PMID: 12056703
  31. Nadella P, Shapiro C, **Otterson GA**, Hauger M, Erdal S, Kraut E, Clinton S, Shah M, Stanek M, Monk P, Villalona-Calero MA. (2002) Pharmacobiologically based scheduling of Capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol, 20:2616-2623. PMID: 12039922
  32. Duan W, Ding H, Zhu W-G, Srinivasan K, **Otterson GA**, Villalona-Calero MA. (2002) RT-PCR-Heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. Biotechniques, 33:58-66. PMID: 12139258

33. Duan W, Ding H, Subler MA, Zhu W-G, Zhang H, Stoner GD, Windle J, **Otterson GA**, Villalona-Calero MA. (2002) Lung-specific expression of mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene, 21:7831-7838. PMID: 12420220
34. Dai Z, Zhu W-G, Morrison CD, Brena RM, Smiraglia DJ, Rush LJ, Ross P, Molina JR, **Otterson GA**, Plass C. (2003) A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Human Molecular Genetics, 12:791-801. PMID: 12651874
35. Zhu W-G, **Otterson, GA**. (2003) The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Current Medicinal Chemistry – Anti-Cancer Agents, 3:187-199. PMID: 12769777
36. Zhu W-G, Srinivasan K, Dai Z, Ding H, Duan W, Yee L, Villalona-Calero MA, Plass C, **Otterson GA**. (2003) Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21Cip1 promoter. Molecular and Cellular Biology, 23:4056-4065. PMID: 12773551
37. Ding H, Duan W, Zhu W-G, Rong J, Srinivasan K, **Otterson GA**, Villalona-Calero, MA. (2003) p21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. Biochemical and Biophysical Research Communications 30:950-956. PMID: 12767922
38. Villalona-Calero MA, Wientjes MG, **Otterson GA**, Kanter S, Young D, Murgo AJ, Fischer B, DeHoff C, Chen D, Yeh T-K, Song S, Grever M, Au JL-S. (2003) A phase I study of low dose Suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clinical Cancer Research 9:3303-3311. PMID: 12960116
39. **Otterson GA**, Herndon JE II, Watson D, Terrenoire J, Green MR, Kindler HL. (2004) Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 44:251-259. PMID: 15084390
40. Dai Z, Popkie AP, Zhu W-G, Timmers CD, Raval A, Tannehill-Gregg S, Morrison CD, Auer H, Kratzke RA, Niehans G, Leone GW, Rosol T, **Otterson GA**, Plass C. (2004) Bone morphogenic protein 3B (BMP3B) silencing in non-small cell lung cancer. Oncogene 23:3521-3529.
41. Zhu W-G, Hileman T, Ke Y, Want P, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C, **Otterson GA**. (2004) 5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 279:15161-15166.
42. Winegarden JD, Mauer AM, **Otterson, GA**, Rudin CM, Villalona-Calero MA, Lanzitti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE. (2004) A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small cell lung cancer. Annals Oncol, 15:915-920. PMID: 15151948

43. Duan W, Gao L, Druhan LJ, Zhu W-G, Morrison C, **Otterson GA**, Villalona-Calero MA. (2004) Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst, 96:1718-1721. PMID: 15547185
44. Villalona-Calero MA, Ritch P, Figueroa JA, **Otterson GA**, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M, Valdivieso M, Geary R, Oliver JW, Holmlund J. (2004) A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res, 10:6086-6093. PMID: 15447994
45. Kindwall-Keller T, **Otterson GA**, Young D, Neki A, Criswell T, Nuovo G, Soong R, Diasio R, Villalona-Calero MA. (2005) Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res, 11:1870-1876. PMID: 15756012
46. **Otterson GA**, Lavelle J, Villalona-Calero MA, Shah M, Chan K, Wei X, Fischer B, Zweibel J, Grever M. (2005) A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors. Investigational New Drugs, 23:555-562. PMID: 16034523
47. Niell HB, Herndon JE II, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, **Otterson G**, Ellerton J, Vokes EE, Green MR. (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23:3752-3759. PMID: 15923572
48. Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, **Otterson GA**, Morrison CD, Smiraglia DJ, Plass C. (2006) Epigenetic regulation of the tumor suppressor gene *TCF21* on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA 103:982-987. PMID: 16415157
49. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, **Otterson GA**, Zhu W-G. (2006) Acetylation of p53 at lysine 373/382 by the HDAC inhibitor Depsipeptide induces expression of p21<sup>waf1/cip1</sup>. Molecular and Cellular Biology 26(7):2782-2790. PMID: 16537920
50. Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, **Otterson GA**, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri M, Villalona-Calero MA. (2006) An assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose intensive chemotherapy in cancer patients. J Clin Oncol 24(12):1852-59. PMID: 16622259
51. Tada Y, Morrison C, **Otterson G**, Plass C. (2006) Epigenetic modulation of tumor suppressor CCAAT/Enhancer Binding Protein  $\square$  (C/EBP $\square$ ) activity in lung cancer. J Natl Cancer Inst 98:396-406. PMID: 16537832

52. Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero MA, **Otterson GA**, Jensen R, Grever M, Murgo AJ, Au JL-S. (2006) Nontoxic suramin as a chemosensitizer in patients: pharmacokinetics, identification and validation of a dosing nomogram. Pharm Res 23(6):1265-1274. PMID: 16715360
53. Villalona-Calero MA, Schaaf LL, Phillips G, **Otterson GA**, Panico K, Duan W, Kleiber B, Shah M, Young D, Wu W-H, Kuhn J. (2007) Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. – Cancer Chemother Pharmacol 59(1):23-33. PMID: 16685529
54. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amica TA, Demmy TL, Feigenberg SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CG, Le QT, Martins R, **Otterson GA**, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Comp Canc Netw. 2006 Jul;4(6):548-82. PMID: 16813724
55. Duan W, Gao L, Wu X, Zhang Y, **Otterson GA**, Villalona-Calero MA. Differential response between the p53 ubiquitin-protein ligases Pirh2 and Mdm2 following DNA damage in human cancer cells. Exp Cell Res. 2006 Oct;312(17):3370-3378. PMID: 16934800
56. Ross P, Grecula J, Bekaii-Saab T, Villalona-Calero MA, **Otterson GA**, Magro C. Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Lasers in Surgery and Medicine. 2006 Dec;38(10):881-889. PMID: 17115382
57. Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Ratain MJ, Levine E, **Otterson GA**, Millard F. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun;13(11):3302-11. PMID: 17545536
58. **Otterson GA**, Villalona-Calero MA, White D, Sharma S, Kris M, Gerber M, Imondi A, Ratain MJ, Ryan C, Schiller J, Sandler A, Kraut M, Mani S, Murren JR. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007 Feb 15;13(4):1246-52. PMID: 17317836
59. Brena RM, Morrison C, Liyanarachchi S, Davuluri RV, Singer GAC, **Otterson GA**, Rush LJ, Plass C. Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Medicine 2007 Mar 27;4(3):e108. PMID: 17388669
60. Smith LT, **Otterson GA**, Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet 2007 Sept;23(9):449-56 Epub 2007 Aug 6. PMID: 17681396

61. Duan W, Gao L, Jin D, **Otterson GA**, Villalona-Calero MA. Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice. Transgenic Res 2008 Jun;17(3):355-66. Epub 2007 Oct 30. PMID: 17968669
62. Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, Lu S, Yu Y, Wang H, McNutt MA, Hu Y-G, Cheng Y, Yang Y, Wu X, **Otterson GA**, Zhu W-G. HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One 2008 June 18;3(6):e2445. PMID: 18560576
63. Villalona-Calero MA, **Otterson GA**, Wientjes MG, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Chen C, Yeh T-K, Song S, Grever M, Au JL-S. Non-cytotoxic suramin as a chemo-sensitizer in patients with advanced non-small cell lung cancer: a phase II study. Ann Onc 2008 Nov;19(11):1903-9. Epub 2008 Jul 3. PMID: 18632723
64. Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, **Otterson GA**, Patel JD, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer. J Natl Compr Canc Netw 2008 Mar;6(3):228-69. PMID: 18377844
65. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, **Otterson GA**, Nuovo G, Marsh CB, Nana-Sinkam SP. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 2008 Sept 5;373(4):607-12. Epub 2008 Jul 3. PMID: 18602365
66. Xu Y, Kolesar JM, Schaaf LJ, Drengler R, Duan W, **Otterson G**, Shapiro C, Kuhn J, Villalona-Calero MA. Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer Chemother Pharmacol 2009 May;63(6):1073-82. (Epub 2008 Sep 16) PMID: 18795290
67. Browning KK, Ferketich AK, **Otterson GA**, Reynolds NR, Wewers ME. A psychometric analysis of quality of life tools in lung cancer patients who smoke. Lung Cancer 2009 Oct;66(1):134-9. (Epub 2009 May 15) PMID: 19181418
68. Browning KK, Wewers ME, Ferketich AK, **Otterson GA**, Reynolds NR. The self-regulation model of illness applied to smoking behavior in lung cancer. Cancer Nursing 2009; 32(4):15-25. Epub. PMID: 19444080
69. Bertino EM, Confer PD, Colonna JE, Ross P, **Otterson GA**. Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer 2009 Oct 1;115(19):4434-41. PMID: 19562772
70. Wu X, Hunter MG, Crawford M, Nuovo GJ, Marsh, CB, **Otterson GA**, Nana-Sinkam SP. MicroRNAs in the pathogenesis of lung cancer. J Thorac Oncol 2009 Aug;4(8):1028-34. PMID: 19474765

71. Duan W, Gao L, Wu X, Hade EM, Gao JX, Ding H, Barsky SH, **Otterson GA**, Villalona-Calero MA. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS ONE 2009;4(5);E5563. PMID: 19440353
72. Kaumaya PTP, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, **Otterson GA**, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE. Phase I active immunotherapy with combination of two chimeric human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009 Nov;27(31):5270-7 (Epub Sep 14). PMID: 19752336
73. Ntukiem N, Arce-Lara C, **Otterson GA**, Kraut E, Cataland S, Bekaii-Saab T. Capped-dose mitomycin C (MMC): a pooled safety analysis from three prospective clinical trials. Cancer Chemother Pharmacol 2009 Jun 9 (Epub). PMID: 19506871
74. Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, **Otterson GA**, Nana-Sinkam SP. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 2009 Oct 23;388(3):483-9. (Epub 2009 Aug 3) PMID: 19654003
75. Duan W, Gao L, Wu X, Wang L, **Otterson GA**, Villalona-Calero MA. MicroRNA-34a is an important component of PRIMA-1 induced apoptotic network in human lung cancer cells. Int J Cancer. 2010 Jul15;127(2):313-20 (Epub Nov 2009). PMID: 19921694
76. Miller AA, Pang H, Hodgson L, Ramnath N, **Otterson GA**, Kelley M, Kratzke RA, Vokes EE. A phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer (CALGB 30602). J Thorac Oncol. 2010 Mar;5(3):380-4. PMID: 20087228
77. Antony GK, Bertino E, Franklin M, **Otterson GA**, Dudek AZ. Small cell lung cancer in never smokers: report of two cases. J Thorac Oncol. 2010 May;5(5):747-8. PMID: 20421768
78. Kosuri KV, Wu X, Wang L, Villalona-Calero MA, **Otterson GA**. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun 2010 Jan 15;391(3):1465-70. Epub 2009 Dec 24. PMID: 20035722
79. Lam ET, Au JL-S, **Otterson GA**, Wientjes MG, Chen C, Shen T, Li X, Bekaii-Saab T, Murgu AJ, Jensen RR, Grever M, Villalona-Calero MA. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2010 Jan 28 Epub. PMID: 20107799
80. Lustberg M, Bekaii-Saab T, Young D, **Otterson GA**, Burak W, Abbas A, McCracken-Bussa B, Lustberg M, Villalona-Calero MA. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in

patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol. 2010 May;5(5):713-8. PMID: 20354452 PMCID: PMC 3641556.

81. **Otterson GA**, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR. Phase I/II study of inhaled doxorubicin combined with platinum based therapy for advanced NSCLC. Clinical Cancer Research. 2010 April 15;16(8):2466-73 (Epub Apr 6). PMID: 20371682
82. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheny RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, **Otterson GA**, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC; NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul;8(7):740-801. PMID: 20679538
83. **Otterson GA**, Hodgson L, Pang H, Vokes EE. Phase II study of the HDAC inhibitor Depsipeptide in relapsed small cell lung cancer. J Thorac Oncol. 2010 Oct;5(10):1644-8. PMID: 20871263
84. Bertino E, Villalona-Calero MA, Ross P, Grever M, **Otterson GA**. Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non small cell lung cancer. Ann Thoracic Surg 2011 Feb;91(2)640.
85. Bertino EM, **Otterson GA**. Benefits and limitations of antiangiogenic agents in non-small cell lung cancer. Lung Cancer 2010 (Epub Sep 29) PMID: 20888062
86. Nuovo GJ, Wu X, Volinio S, Yan F, di Leva G, Chin N, Nicol AF, Jiang J, **Otterson G**, Schmittgen TD, Croce C. Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. Diagn Mol Pathol 2010 Sept;19:135-43. PMID: 20736742.
87. Yan F, Wu X, Crawford C, Duan W, Wilding EE, Gao L, Nana-Sinkam SP, Villalona-Calero MA, Baiocchi RA, **Otterson GA**. The search for an optimal DNA, RNA and protein detection by *in situ* hybridization, immunohistochemistry and solution based methods. Methods 2010 (Epub Oct 1). PMID: 20888418.
88. Burris H, Stephenson J, **Otterson GA**, Stein M, McGreivy J, Sun Y-N, Ingram M, Ye Y, Schwartzberg LS. Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-cisplatin in patients with advanced cancer. Journal of Oncology. Volume 2011 (2011), Article ID 853931, 11 pages, (doi: 10.1155/2011/853931).
89. Edelman JM, **Otterson GA**, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R. Multicenter phase II trial of motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol 2011 Apr;6(4):786-9 (Epub Feb 1.)

90. Monk P, Villalona M, Larkin J, **Otterson GA**, Spriggs D, Hannah A, Gillian C, Johnson R, Hensley M. A phase I study of KOS-862 (Epothilone D) co-administered with carboplatin (paraplatin®) in patients with advanced solid tumors, (DOI: 10.1007/s10637-011-9731-4). Accepted, Investigational New Drugs, August 1, 2011. PMID: 21826439. Impact Value: 3.007 \
91. Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. *Expert Opin Investig Drugs*. 2011 Aug;20(8):1151-8. PMID: 21699444 Impact Value: 4.337
92. Herbst RS, Ansara R, Bustin F, Flynn P, Hart L, Hsia T-H, **Otterson GA**, Vlahovic G, Soh, C-H, O'Connor, P, Hainsworth J. A phase III, placebo-controlled, randomized, double-blind, clinical trial (BeTa) to evaluate the efficacy of bevacizumab in combination with erlotinib, compared with erlotinib alone, for treatment of advanced non-small cell lung cancer (NSCLC) after failure of standard first line chemotherapy. Accepted.
93. Thierry J, Kindler H, Kratzke R, Vokes E, Green M, Wang X, **Otterson GA**. Vatalanib in malignant mesothelioma: A Phase II trial by the Cancer and Leukemia Group B (CALGB 30107) Lung Cancer. Lung Cancer 2011 Accepted.
94. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, **Otterson GA**, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. National Comprehensive Cancer Network. Malignant pleural mesothelioma. Clinical practice guidelines in oncology. *Natl Compr Canc Netw*. 2012 Jan;10(1):26-41. PubMed PMID: 22223867.
95. Schütte W, Krzakowski M, Massuti B, **Otterson GA**, Lizambri R, Wei H, Berger D, Chen Y. Palifermin reduces dysphagia in patients with locally advanced unresected non-small cell lung cancer undergoing concurrent chemoradiotherapy. J Thorac Oncol. Jan;7(1):157-64. PubMed PMID: 22011667. Impact Value: 4.040
96. Wood DE, Eapen GA, Ettinger DS, Hou L, Jackman D, Kazerooni E, Klippenstein D, Lackner RP, Leard L, Leung AN, Massion PP, Meyers BF, Munden RF, **Otterson GA**, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Schabath MB, Sequist LV, Tong BC, Travis WD, Unger M, Yang SC. Lung cancer screening. *J Natl Compr Canc Netw*. 2012 Feb;10(2):240-65. PubMed PMID: 22308518.
97. Ferketich AK, **Otterson GA**, King M, Hall N, Browning KK, Wewers ME. A pilot test of a combined tobacco dependence treatment and lung cancer screening program. *Lung Cancer*. 2012 May;76(2):211-5. Epub 2011 Nov 15. PubMed PMID: 22088938.
98. Jahan T, Gu L, Kratzke R, Dudek A, **Otterson GA**, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). *Lung Cancer*. 2012 Jun;76(3):393-6.



Epub 2011 Dec 22. PubMed PMID: 22197613.

99. Dudek AZ, Pang H, Kratzke RA, **Otterson GA**, Hodgson L, Vokes EE, Kindler HL; Cancer and Leukemia Group B. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. *J Thorac Oncol.* 2012 Apr;7(4):755-9. PubMed PMID: 22425926; PubMed Central PMCID: PMC3308128.
100. Zhao W, Huang CC, **Otterson GA**, Leon ME, Tang Y, Shilo K, Villalona MA. Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer. *J Oncol.* 2012;2012:957437. Epub 2012 Apr 30. PMID: 22619677
101. Zornosa C, Vandergrift JL, Kalemkerian GP, Ettinger DS, Rabin MS, Reid M, **Otterson GA**, Koczywas M, D'Amico TA, Niland JC, Mamet R, Pisters KM. First-Line Systemic Therapy Practice Patterns and Concordance with NCCN Guidelines for Patients with Metastatic NSCLC Treated at NCCN Institutions. *J Natl Compr Canc Netw.* 2012 Jul 1;10(7):847-856
102. Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, **Otterson GA**, Grever MR, Bekaii-Saab T. A Phase I Study of Prolonged Infusion of Triapine in Combination with Fixed Dose Rate Gemcitabine in Patients with Advanced Solid Tumors. *Invest New Drugs.* June 2013 PMID: 22847785 Impact Factor: 3.357
103. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, O'Malley J, Osarogiagbon RU, **Otterson GA**, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM. Non-small cell lung cancer. *J Natl Compr Canc Netw.* 2012 Oct 1;10(10):1236-71 PMID: 23054877
104. Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, **Otterson GA**, Villalona-Calero MA. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. *Transl Res.* 2012 Oct 11. S1931-5244(12) PMID: 23063585 Impact Factor: 2.986
105. Martin LK, Grecula J, Jia G, Wei L, Yang X, **Otterson GA**, Wu X, Harper E, Kefauver C, Zhou BS, Yen Y, Bloomston M, Knopp M, Ivy SP, Grever M, Bekaii-Saab T. A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. 2012 Nov 15;84(4):e475-81 PMID: 22818416 Impact Factor: 4.105
106. Martin KL; **Otterson GA**; Bekaii-Saab,T. Photodynamic Therapy (PDT) May Provide Effective Palliation in the Treatment of Primary Tracheal Carcinoma: A Small Case Series. *PhotoMed and Laser Surgery.* 2012 Nov; 30(11): 668-671

Impact Factor: 1.26

107. Gandhi L, Drappatz J, Ramaiya NH, **Otterson GA**. High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. *J Thor Onco*. 2013 Jan; 8(1):e3-5 Impact Factor 3.66
108. Chu BF, Karpenko MJ, Liu Z, Aimiwu J, Villalona-Calero MA, Chan KK, Grever MR, **Otterson GA**. Phase I study of 5-aza-2-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. *Cancer Chemother Pharmacol*. 2013 Jan; 71(1):115-21. PMID 23053268 Impact Factor: 2.883
109. Bertino EM; Bekaii-Saab T; Fernandez S; Diasio RB; Karim NA; **Otterson GA**; Villalona-Calero MA. A phase II study of modulated-capecitabine and docetaxel in chemo-naïve patients with advanced non-small cell lung cancer (NSCLC). 2013 Jan; 79(1):27-32 Impact Factor 3.43
110. Ferketich AK, Niland JC, Mamet R, Zornosa C, D'Amico TA, Ettinger DS, Kalemkerian GP, Pisters KM, Reid ME, **Otterson GA**. Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort. *Cancer*. 2013 Feb. PMID: 23023590 Impact Factor: 4.771
111. Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, **Otterson GA**, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Thymomas and Thymic Carcinomas: Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2013 May 1;11(5):562-76. PMID: 23667206
112. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, **Otterson GA**, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, version 2.2013. *J Natl Compr Canc Netw*. 2013 Jun 1;11(6):645-53; quiz 653. PMID: 23744864
113. Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, **Otterson GA**. Cellular Localization of Protein Arginine Methyltransferase-5 Correlates with Grade of Lung Tumors. *Diagn Pathol*. 2013 Dec 10; 8(1):201. PMID 24326178 Impact Factor: 1.850
114. Yu Y, Kwak K, Agarwal K, Marras A, Wang C, Mao Y, Huang X, Ma J, Yu B, Lee R, Vachani A, Marcucci G, Byrd J, Muthusamy N, **Otterson GA**, Huang K, Castro C, Paulaitis M, Nana-Sinkam P, Lee LJ. Detection of Extracellular RNAs in Cancer and Viral Infection via Tethered Cationic Lipoplex Nanoparticles Containing Molecular Beacons. *Analytical Chemistry*. 2013 Dec. 85(23):11265-11274. PMID

24102152. Impact Factor: 5.70

115. Ou SH, Janne PA, Bartlett CH, Tang Y, Kim DW, **Otterson GA**, Crino L, Selaru P, Cohen DP, Clark JW, Riely GJ. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. *Ann Oncol.* 2014 Feb;25(2):415-22. PMID: 24478318 Impact Factor: 7.38
116. Heist RS, Wang X, Hodgson L, **Otterson GA**, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA. CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. *J Thorac Oncol.* 2014 Feb;9(2):214-21. PMID: 24419419 Impact Factor: 4.473
117. Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, **Otterson GA**, Carson WE 3<sup>rd</sup>, Marcucci G, Bloomfield CD, de la Chapelle A. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. *Proc Natl Acad Sci USA.* 2014 Mar 18; 111(11):4179-84. Impact Factor: 9.74
118. Shtivelman E, Hensing T, Simon GR, Dennis PA, **Otterson GA**, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. *Oncotarget.* 2014 Mar 30;5(6):1392-433. PMID: 24722523 Impact Factor: 1.894
119. Gitlitz BJ, Bernstein E, Santos ES, **Otterson GA**, Milne G, Syto M, Burrows F, Zaknoen S. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. *J Thorac Oncol.* 2014 Apr;9(4):577-82 PMID: 24736085 Impact Factor: 4.473
120. Chen W, Brodsky SV, Zhao W, **Otterson GA**, Villalona-Calero M, Satoskar AA, Hasan A, Pelletier R, Ivanov I, Ross P, Nadasdy T, Shilo K. Y-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization analysis. *Hum Pathol.* 2014 May;45(5):1065-70. Impact Factor: 0.997
121. Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiwu J, Gao Y, Li J, **Otterson GA**, Hicks WJ, Socinski MA, Villalona-Calero MA. Erlotinib in African Americans with Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study with Genetic and Pharmacokinetic Analyses. *Clin Pharmacol Ther.* 2014 Aug;96(2):182-91 PMID: 24781527 Impact Factor: 1.947
122. Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou XP, Frankel W, **Otterson GA**, Zhao W. Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations. *Int J Environ Res Public Health.* 2014 Sep;11(9):8645-60 Impact Factor: 1.998 PMID:25158139

123. Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou XP, Frankel W, **Otterson GA**, Beall HD, Zhao W. Increased NQO1 but not c-MET and Survivin Expression in Non-Small Cell Lung Carcinoma with KRAS Mutations. *International Journal of Environmental Research and Public Health*. 2014 Sep 12;11(9):9491-502. Impact Factor: 1.998 PMID:25222473
124. Ettinger DS, Wood DE, Akerley W, Bazhenova H, Camidge DR, Cheney RT, Chitiec LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, **Otterson GA**, Patel JD, Pisters KM, Reckamp K, Riehl GJ, Rohen E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. *J Natl Compr Canc Netw*. 2014 Dec;12(12):1738-61. Impact Factor: 4.237 PMID:25505215
125. Duan W, Gao L, Aguila B, Kalvala A, **Otterson GA**, Villalona-Calero MA. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. *Front Oncol*. 2014 Dec 19; 4:368. PMID:25566506
126. Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, **Otterson GA**, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. *J Clin Oncol*. 2015 Jan 10;33(2):189-94. Impact Factor: 17.960 PMID: 25452446
127. Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Leung AN, Makani SS, Massion PP, Meyers BF, **Otterson GA**, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Sequist LV, Tong BC, Travis WD, Yang SC, Gregory KM, Hughes M. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*. 2015 Jan;13(1):23-34; quiz 34. Impact Factor: 4.237 PMID: 25583767
128. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, **Otterson GA**, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase II, single-arm trial. *Lancet Oncol*. 2015 Mar;16(3):257-65. Impact Factor: 24.725 PMID: 25704439
129. Bond DA, Dunavin N, **Otterson GA**. Mutational profiling of second primary lung cancers in patients who have received radiation for the treatment of Hodgkin's disease. *Cancer Invest*. 2015 Mar; 33(3):86-8. Impact Factor: 2.060 PMID: 25615851

130. Kalvala A, Gao L, Aguila B, Reese T, **Otterson GA**, Villalona-Calero MA, Duan W. Overexpression of Rad51C splice variants in colorectal tumors. *Oncotarget*. 2014 Dec 30 2015 Apr 20;6(11):8777-87 Impact Factor: 6.627 PMID:25669972
131. Ettinger DS, Wood DE, Akerley W, Bazhenova H, Borghaei H, Camidge DR, Cheney RT, Chitiec LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, **Otterson GA**, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohen E, Schild S, ShapiroTA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 6.2015. *J Natl Compr Canc Netw*. 2015 May; 13(5):515-24 PMID: 25964637 Impact Factor: 4.237
132. Ready NE, Pang HH, Gu L, **Otterson GA**, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study – CALGB 30504 (Alliance). *J. Clinical Oncology*. 2015 May 20;33(15):1660-5 PMID: 25732163 Impact Factor: 17.960
133. Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, **Otterson GA**, Mekhail T, Snell M, Kuebler JP, Sharma N, Dowlati A. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. *Oncologist*. 2015 Nov;20(11):1298-303 PMID: 23591432 IF: 4.865
134. Burkart J, Shilo K, Zhao W, Ozkan E, Ajam A, **Otterson GA**. Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations. *Case Rep Pulmonol*. 2015 Epub 2015 Aug 23. PMID: 26123189
135. Ozkan E, West A, Dedelaw JA, Chu BF, Zhao W, Yildaz VO, **Otterson GA**, Shilo K, Ghosh S, King M, White RD, Erdal BS. CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung. *AJR Am J Roentgenol*. 2015 Nov;205(5):1016-25 IF: 2.731
136. Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, **Otterson GA**. Stromal Caveolin-1 is Associated with Response and Survival in a Phase II Trial of nab-Paclitaxel with Carboplatin for Advanced NSCLC Patients. *Clin Lung Cancer*. 2015 Nov. 16(6):466-474 PMID: 23079156 IF: 3.104
137. Ettinger DS, Wood DE, Akerley W, Bazhenova H, Borghaei H, Camidge DR, Cheney RT, Chitiec LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, **Otterson GA**, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild S, ShapiroTA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-small cell lung cancer, version 4.2016. *J Natl Compr Canc Netw*. 2016 Mar; 14(3):255-64 PMID:

26957612 Impact Factor: 4.23

138. Villalona-Calero MA, Lam E, **Otterson GA**, Zhao W, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. *Cancer*. 2016 Mar 15;122(6):875-83 PMID: 26709987 Impact Factor: 5.068
139. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr F, Karlovich CA, Harding TC, Durkin KA, **Otterson GA**, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun*. 2016 Jun 10;7:11815. PMID: 27283993
140. Kalvala A, Gao L, Aguila B, Dotts K, Rahman M, Nana-Sinkam SP, Zhou X, Wang QE, Amann J, **Otterson GA**, Villalona-Calero MA, Duan W. Rad51C-ATXN7 fusion gene expression in colorectal tumors. *Mol Cancer*. 2016 Jun 13;15(1):47. PMID: 27296891 Impact Factor: 5.888
141. Chu BF, **Otterson, GA**. Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm. *Clin Lung Cancer*, 2016 Jun 8. pii: S1525-7304(16)30136-X. PMID: 27381269 IF:3.104
142. Rahman MA, Barger JF, Lovat F, Gao M, **Otterson GA**, Nana-Sinkam P. Lung cancer exosomes as drivers of epithelial mesenchymal transition. *Oncotarget*. 2016 Jun 23. PMID: 27363026 Impact Factor: 6.627
143. Halasz LM, Uno H, Hughes M, D'Amico T, Dexter EU, Edge SB, Hayman JA, Niland JC, **Otterson GA**, Pistors KM, Theriault R, Weeks JC, Punglia RS. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. *Cancer*. 2016 Jul 1;122(13):2091-100 PMID: 27088755 Impact Factor: 5.068
144. Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, **Otterson GA**. A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. *Mol Cancer Ther*. 2016 Sep;15(9):2244-50. PMID: 27458141
145. Chiappori AA, **Otterson GA**, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM. A randomized Phase II study of Linsitinib (OSI-906) versus the Topotecan in patients with relapsed small-cell lung cancer. *Oncologist* 2016 Oct;21(10): 1163-1164 PMID: 27694157 PMCID: PMC5061534 Impact Factor: 2.01
146. Shukuya T, Mori K, Amann JM, Bertino EM, **Otterson GA**, Shields PG, Morita S, Carbone DP. Relationship between overall survival and response of progression-free survival in advanced non-small cell lung cancer patients treated with anit PD-

- 1/PD-L1 antibodies. *J Thorac Oncol.* 2016 Nov; 11(11):1927-1939. PMID: 27496650 Impact Factor: 5.800
147. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, **Otterson GA**, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun.* 2016 Nov 14;7:13513 PMID: 27841271 PMCID: PMC5114547
148. Chu BF, **Otterson, GA**. Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm. *Clin Lung Cancer*, 2016 Nov. 17(6):493-506. PMID: 27381269 IF:3.104 – Review
149. Ou S, Govindan R, Eaton KD, **Otterson GA**, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F. Phase I results from a study of Crizotinib in combination with Erlotinib in patients with advanced nonsquamous non-small cell lung cancer. *J Thorac Oncol.* 2017 Jan;12(1):145-151 PMID: 27697581 Impact Factor: 5.800
150. Owen D, **Otterson GA**. New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases. *J Thorac Dis.* 2017 Feb;(2):E158-E161 PMID: 28275504 Impact Factor: 1.649
151. Aisner DL, Sholl LM, Berry L, Rossi M, Chen H, Fujimoto J, Moreira AL, Ramalingam S, Villaruz LC, **Otterson GA**, Haura EB, Politi K, Glisson BS, Cetnar J, Garon E, Schiller J, Waqar S, Sequist LV, Brahmer JR, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2). *Clin Cancer Res.* 2017 Dec 7. pii: clincanres.2289.2017 PMID: 29217530
152. Yao K, Zhao W, Bajestani S, Gru A, **Otterson G**, Shilo K. Comprehensive Next-Generation Sequencing Analysis is Recommended for the Management of Patients With Melanoma. *Appl Immunohistochem Mol Morphol.* 2017 Nov 22. PMID: 29176444
153. Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, **Otterson GA**, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S. Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer. *Oncotarget.* 2017 Sep 1;8(44):75822-75833. PMID: 29100271
154. Shukuya T, Patel S, Shane-Carson K, He K, Bertino EM, Shilo K, **Otterson GA**, Carbone DP. Lung Cancer Patients with Germline Mutations Detected by Next-

- Generation Sequencing and/or Liquid Biopsy. *J Thorac Oncol*. 2017 Oct 5. PMID: 28989037
155. Yao K, Zhao W, Bajestani S, Gru A, **Otterson G**, Shilo K. Malignant Melanoma Presenting as Thoracic Midline Malignancy: Clinicopathologic and Molecular Features. *Appl Immunohistochem Mol Morphol*. 2018 Jan;26(1):46-53. PMID: 28777149
156. Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, **Otterson GA**, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). *Clin Cancer Res*. 2018 Mar 1;24(5):1038-1047. PMID: 29217530
157. Miller ED, Fisher JL, Haglund KE, Grecula JC, Xu-Welliver M, Bertino EM, He K, Shields PG, Carbone DP, Williams TM, **Otterson GA**, Bazan JG. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2018 Mar;13(3):426-435. PMID: 29326090
158. Barney CL, Scoville N, Allan E, Ayan A, DiCostanzo D, Haglund KE, Grecula J, Williams T, Xu-Welliver M, **Otterson GA**, Bazan JG. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. *Int J Radiat Oncol Biol Phys*. 2018 Mar 1;100(3):748-755. doi: 10.1016/j.ijrobp.2017.11.025. Epub 2017 Nov 23. PMID: 29413286
159. Cho JH, Oezkan F, Koenig M, **Otterson GA**, Herman JG, He K. Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. *Curr Pharmacol Rep*. 2017 Dec;3(6):360-373. Epub 2017 Oct 14. PMID: 29503796
160. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, **Otterson GA**, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus ipilimumab in Lung Cancer with a High Tumor Mutational Burden. *N Engl J Med*. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16. PMID: 29658845
161. Owen D, Chu B, Lehman AM, Annamalai L, Yearley JH, Shilo K, **Otterson GA**. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. *J Thorac Oncol*. 2018 Apr 24. PMID: 29702286
162. Ready N, Hellmann MD, Awad MM, **Otterson GA**, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS. *First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung*



- Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.* J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20. PMID: 30785829
163. Alvarez JGB, **Otterson GA**. *Agents to treat BRAF-mutant lung cancer.* Drugs Context. 2019 Mar 13;8:212566. doi: 10.7573/dic.212566. eCollection 2019. Review. PMID: 30899313
164. Duan W, Gao L, Kalvala A, Aguila B, Brooks C, Mo X, Ding H, Shilo K, **Otterson GA**, Villalona-Calero MA. *Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.* Int J Cancer. 2019 Nov 1;145(9):2418-2426. doi: 10.1002/ijc.32279. Epub 2019 Apr 13. PMID: 30873587
165. Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, **Otterson GA**, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. *Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.* J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4. PMID: 31163011
166. Jain NA, **Otterson GA**. *Immunotherapy in inoperable stage III non-small cell lung cancer: a review.* Drugs Context. 2019 Jun 17;8:212578. doi: 10.7573/dic.212578. eCollection 2019. Review. PMID: 31258616
167. Owen DH, Williams TM, Bertino EM, Mo X, Webb A, Schweitzer C, Liu T, Roychowdhury S, Timmers CD, **Otterson GA**. *Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.* Lung Cancer. 2019 Aug;134:167-173. doi: 10.1016/j.lungcan.2019.06.017. Epub 2019 Jun 17. PMID: 31319977
168. Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K, Bertino EM, Shields PG, Carbone DP, Verschraegen CF, Presley CJ, **Otterson GA**, Kendra K, Owen DH. *Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.* J Cancer Res Clin Oncol. 2019 Oct;145(10):2541-2546. doi: 10.1007/s00432-019-02982-4. Epub 2019 Jul 31. PMID: 31367835
169. Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeño J, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S, Crinò L, Planchard D, Butts C, Drlon A, Wojcik-Tomaszewska J, **Otterson GA**, Agrawal S, Li A, Penrod JR, Brahmer J. *Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.* Lancet Oncol. 2019 Oct;20(10):1395-1408. doi: 10.1016/S1470-2045(19)30407-3. Epub 2019 Aug 14. PMID: 31422028
170. Revelo AE, Martin A, Velasquez R, Kulandaisamy PC, Bustamante J, Keshishyan S, **Otterson G**. *Liquid biopsy for lung cancers: an update on recent*

- developments*. Ann Transl Med. 2019 Aug;7(15):349. doi: 10.21037/atm.2019.03.28. Review. PMID:31516895
171. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Martins RG, **Otterson GA**, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K; OCN, Hughes M. *NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020*. J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472. doi: 10.6004/jnccn.2019.0059. PMID: 31805526
  172. Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, **Otterson GA**, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. *Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials*. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70. PMID: 31838015
  173. Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, **Otterson GA**, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK. *Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration*. Nat Med. 2020 Jan;26(1):47-51. doi: 10.1038/s41591-019-0716-8. Epub 2020 Jan 13. PMID: 31932802
  174. Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, **Otterson GA**, de Lima Lopes G, Walker PR. *Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort*. Cancer Immunol Immunother. 2020 Mar 5. doi: 10.1007/s00262-020-02536-5. [Epub ahead of print] PMID: 32140762
  175. Baek J, Owen DH, Merritt RE, Shilo K, **Otterson GA**, D'Souza DM, Carbone DP, Kneuert P.
  176. *Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations*. Clin Lung Cancer. 2020 Feb 25. pii: S1525-7304(20)30041-3. doi: 10.1016/j.clcc.2020.02.016. [Epub ahead of print] No abstract available. PMID: 32184051

Book Chapters:

1. Kaye FJ, Kim YW, **Otterson GA**. Molecular Biology of Lung Cancer. In: Cowell J.K., ed. Molecular Genetics of Cancer, Bios Scientific Publishers LTD, Oxford, UK, 1995.
2. Kaye FJ, Chen W, Khleif SN, **Otterson GA**. Lung cancer, molecular and cellular abnormalities. In: Bertino, J. R., ed. Encyclopedia of Cancer, Academic Press, Inc., San Diego, CA, 1996.
3. **Otterson GA**, Flynn G, Kaye FJ. The STCH protein. In: Gething, M.J., ed. Guidebook to Molecular Chaperones and Protein Folding Factors, Oxford University Press, Oxford, UK, 1997.
4. Valentine C, **Otterson GA**, Nadasdy T, Hebert LA. Paraneoplastic Glomerulopathies. In: Cohen, E., ed. Cancer and the Kidney, Oxford University Press, Oxford, UK, 2005.
5. Dai Z, Kosuri K, **Otterson GA**. Mechanisms of DNA Demethylating Agents Against Cancer Progression. In Esteller M, ed. DNA Methylation, Epigenetics and Metastasis, Springer Life Sciences, Dordrecht, The Netherlands, 2005.
6. **Otterson GA**. Lung Cancer. In: Rakel RE, Bope ET ed. Conn's Current Therapy, 2009 Edition, Elsevier, Amsterdam, The Netherlands.

Book Reviews:

1. **Otterson GA**. (2002) A Question of Intent: A Great American Battle with a Deadly Industry. By David Kessler, in Oncology Times, 24: 75-76.

Journal Reviews:

1. Wu X, Yan F, Duan W, Gao L, Crawford M, Nuovo GJ, Lawler S, Chen H, Nana-Sinkam SP, Villalona-Calero MA, **Otterson GA**. MicroRNA miR205 enhances cisplatin induced apoptosis in lung cancer cells. *Personalized Medicine*, May 2012, Vol. 9, No. 3, Pages 329-332

Invited Commentary/Opinion/Letters:

1. **Otterson G**. (2001) The human genome and lung cancer. *Advance, for Managers of Respiratory Care*, 10:50-51.
2. **Otterson GA**. (2004) We must give lung cancer the attention it deserves. *Frontiers Magazine*, Fall edition.
3. **Otterson GA**. (2004) Letter to *Oncology News International*, Response to Inhalational Chemotherapy.

4. Kosuri KV, **Otterson GA.** (2004) Commentary on “Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine,” Oncology 18:1173-6.
5. Otterson GA. (2004) We must give lung cancer the attention it deserves. *Frontiers*, Fall, 2004, 2.

#### **Published Abstracts and Presentations (selected)**

1. McGinn, C.J., Drake, J.C., Glennon, M.C., **Otterson, G.**, Allegra, C.J., Johnston, P.G., Kinsella, T.J. An evaluation of the G0/G1 arrest point in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines. Proceedings of the American Association for Cancer Research, Washington, D.C., 1996.
2. Hausner, P., **Otterson, G.**, Mcelroy, K., Curt, G.A. Performance status in clinical oncology: different import in protocol and nonprotocol settings. Proceedings of the American Society of Clinical Oncology, Philadelphia, PA, 1996.
3. **Otterson, G.A.**, Chen, W., Geradts, J., Niklinska, W., Khleif, S.N., Coxon, A.B., Kaye, F.J. Characterization of FHIT protein expression and analysis of growth suppression in human cancer cells. Proceedings of the American Association for Cancer Research, San Diego, CA, 1997.
4. Coxon, A.B., Ward, J., **Otterson, G.A.**, Khleif, S.N., Chen, W., Zajac-Kaye, M., Kaye, F.J. Genetic analysis of a mouse model for neuroendocrine tumors. Proceedings of the American Association for Cancer Research, San Diego, CA, 1997.
5. **Otterson, G.A.**, Coxon, A.B., Kaye, F.J. A classification of low penetrant familial retinoblastoma alleles based on biochemical analyses of mutant RB proteins. Proceedings of the American Association for Cancer Research, New Orleans, LA, 1998.
6. Dai, Z., Ross, P., **Otterson, G.A.**, Plass, C. Global DNA methylation changes in primary lung cancer. The Ohio State University Comprehensive Cancer Center Scientific Retreat, Cherry Valley Lodge, Newark, OH, 1999.
7. Zhu, W.-G., Lakshmanan, R., **Otterson, G.A.** Histone deacetylase and DNA methyltransferase inhibitors act cooperatively to reverse transcriptional silencing induced by DNA hypermethylation. The Ohio State University Comprehensive Cancer Center Scientific Retreat, Cherry Valley Lodge, Newark, OH, 1999.
8. Zhu, W.-G., Lakshmanan, R., **Otterson, G. A.** Histone deacetylase and DNA methyltransferase inhibitors act cooperatively to reverse transcriptional silencing induced by DNA hypermethylation. American Association for Cancer Research, San Francisco, CA, 2000.
9. Villalona-Calero M.A., Shapiro C., **Otterson G.A.**, Hauger M., Kraut E., Clinton S., Shah M., Stanek M., Monk P. Phase I study of weekly docetaxel in combination

- with capecitabine in patients with solid malignancies. 23<sup>rd</sup> Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2000.
10. Villalona-Calero, M.A., Kuhn, J., Drengler, R., Schaaf, L., **Otterson, G.A.**, Shapiro, C., Thurman, A., Diab, S., Hammond, L., Rowinsky, E., Felton, S., Hauger, M., Monroe, P., Kolesar, J., Phase I and biological study of mitomycin C (MMC) as a modulator of irinotecan's (CPT-11) activity in patients with solid malignancies. 12<sup>th</sup> NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 2000.
  11. Zhu, W.-G., Dai, Z., Lakshmanan, R., Plass, C., **Otterson, G.A.** Inhibition of histone deacetylase and DNA methyltransferase activity differentially affects p16<sup>INK4a</sup> vs. p19<sup>INK4d</sup> protein expression. American Association for Cancer Research, New Orleans, LA, 2001.
  12. Duan, W., Ding, H., Subler, M.A., Windle, J., Stoner, G.D., **Otterson, G.A.**, Villalona-Calero, M.A. Lung specific expression of mutant p53 (273H) in mice. American Association for Cancer Research, New Orleans, LA, 2001.
  13. White, D., Kris, M., **Otterson, G.A.**, Imondi, A., Allen, J.N., Sharma, S. Phase I clinical and pharmacologic study of inhaled doxorubicin in adults with advanced solid tumors affecting the lungs. Proceedings of ASCO, San Francisco, CA, 2001.
  14. Villalona-Calero, M.A., Kuhn, J., Drengler, R., Schaaf, L., **Otterson, G.A.**, Shapiro, C., Thurman, A., Diab, S., Hammond, L., Von Hoff, D., Felton, S., Hauger, M., Monroe, P., Rowinsky, E., Kolesar, J. Pharmacologically-based phase I study of mitomycin c (MMC) as a modulator of irinotecan (CPT-11) antitumor activity. Proceedings of the American Society of Clinical Oncology, San Francisco, CA, 2001.
  15. Rudin, C., **Otterson, G.A.**, George, C.M., Mauer, A.M., Szeto, L., Vokes, E.E. A phase I/II trial of genasense and paclitaxel in chemorefractory small cell lung cancer. Proceedings of the American Society of Clinical Oncology, San Francisco, CA, 2001.
  16. Hoffman, P.C., Mauer, A.M., **Otterson, G.A.**, Rudin, C.M., Villalona, M.A., Golomb, H.M., Wade, J.L., Lanzotti, V.J., Ansari, R.H., Szeto, L.L., Vokes, E.E. Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, San Francisco, CA, 2001.
  17. Villalona-Calero, M.A., **Otterson, G.A.**, Wuintges, G., Au, J. A phase I pharmacokinetic (PK), and biological study of FGF inhibition modulating paclitaxel/carboplatin (P/C) chemotherapy in non-small cell lung cancer (NSCLC) patients (pts). 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Miami Beach, FL, 2001.
  18. Ding, H., Duan, W., Zhu, W.-G., Ju, R., Subler, M.A., **Otterson, G.A.**, Villalona-Calero, M.A. Mechanisms of regulation of Chk2 expression after exposure to the topoisomerase II inhibitor genistein. 2001 AACR-NCI-EORTC International

- Conference on Molecular Targets and Cancer Therapeutics, Miami Beach, FL, 2001.
19. Villalona-Calero, M.A., Figueroa, J., Nadella, P., **Otterson, G.A.**, Snider, P., Browning, K., D'Amato, N.P., Geary, R. Phase I and pharmacokinetic (PK) study of the protein kinase C alpha (PKC- $\alpha$ ) inhibitor ISIS-3521 in combination with cisplatin and gemcitabine in patients with solid malignancies. 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Miami Beach, FL, 2001.
  20. Chen, D., Song, S., Yeh, T., Au, J.L.-S., Villalona-Calero, M., **Otterson, G.**, Kanter, S., Wientjes, M.G. Population pharmacokinetic analysis of suramin in combination with paclitaxel and carboplatin in nonsmall cell lung cancer patients. 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Miami Beach, FL, 2001.
  21. Beal, M.D., Srinivasan, K., Zhu, W.-G., **Otterson, G.A.** Regulation of p53 function through acetylation. AACR Cancer and Chromosomal Organization / Epigenetics of Cancer, Palm Desert, CA, 2001.
  22. **Otterson, G.A.**, Browning, K.K., Wewers, M.E., Villalona-Calero, M.A., Ross, P. Smoking characteristics of lung cancer patients and their family members. The Ohio State University Comprehensive Cancer Center Scientific Retreat, Dublin, OH, 2002.
  23. Ding, H., Duan, W., Zhu, W.-G., Srinivasan, K., **Otterson, G.A.**, Villalona-Calero, M.A. ATM participates in topoisomerase II inhibitors induced p21 expression in p53 null cell lines. The Ohio State University Comprehensive Cancer Center Scientific Retreat, Dublin, OH, 2002.
  24. Duan, W., Ding, H., Zhu, W.-G., Zilliox, L., Srinivasan, K., **Otterson, G.A.**, Villalona-Calero, M.A. Comparative expression analysis between p16<sup>INK4a</sup> gene and p21<sup>WAF1/CIP1</sup> gene in lung adenocarcinomas of the SP-C-p53 (273H) transgenic mice. The Ohio State University Comprehensive Cancer Center Scientific Retreat, Dublin, OH, 2002.
  25. Zhu, W.-G., Dai, Z., Srinivasan, K., Ding, H., Duan, W., Villalona-Calero, M.A., Plass, C., **Otterson, G.A.** Methylated Sp1 binding sites are responsible for p21 silencing. The Ohio State University Comprehensive Cancer Center Scientific Retreat, Dublin, OH, 2002.
  26. Chen, D., Yeh, T., Song, S., Au, J.L., Villalona-Calero, M., **Otterson, G.**, Kantor, S., Chan, K., Wientjes, M.G. Pharmacokinetics of low dose Suramin in combination with paclitaxel and carboplatin in non-small cell lung cancer patients. American Association for Cancer Research, San Francisco, CA, 2002.
  27. Ding, H., Duan, W., Zhu, W.-G., **Otterson, G.A.**, Villalona-Calero, M. ATM participates in topoisomerase II inhibitors induced p21 expression in p53 null cell lines. American Association for Cancer Research, San Francisco, CA, 2002.

28. Duan, W., Ding, H., Zhu, W.-G., Zilliox, L., Srinivasan, K., **Otterson, G.A.**, Villalona-Calero, M. Expression of p16<sup>INK4a</sup> gene and p21<sup>WAF1/CIP1</sup> gene in lung adenocarcinomas of the SPC-p53(273H) transgenic mice. American Association for Cancer Research, San Francisco, CA, 2002.
29. Zhu, W.-G., Dai, Z., Srinivasan, K., Ding, H., Duan, W., Villalona, M., Plass, C., **Otterson, G.A.** Methylated Sp1 binding sites are responsible for p21 silencing. American Association for Cancer Research, San Francisco, CA, 2002.
30. Dai, Z., Zhu, W.-G., Popkie, A.P., Wali, A., Pass, H.I., Timmers, C.D., Leone, G.W., Niehans, G.A., Kratzke, R.A. **Otterson, G.A.**, Plass, C. Promoter methylation and silencing of bone morphogenetic protein 3B (BMP3B) in non-small cell lung cancer identifies a novel lung cancer gene on 10q11. American Association for Cancer Research, San Francisco, CA, 2002.
31. **Otterson, G.A.**, Browning, K.K., Wewers, M.A., Villalona-Calero, M.A., Ross, P. Smoking characteristics of lung cancer patients and their family members. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002.
32. Monk, P.A. Waite, R., Kuhn, J., **Otterson, G.A.**, Shah, M., Rhoades, C., Hauger, M., Caligiuri, M.A., Villalona-Calero, M.A. Improved tolerability to dose intensive chemotherapy with tumor necrosis factor (TNF) blockade. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002.
33. Von Pawel, J., Shepherd, F., Gatzmeier, U., Natale, R.B., O'Brien, M.E.R., **Otterson, G.A.**, Schwartzberg, L., Kimmell, K.A., Gulyas, S., Copley-Merriman, C., Grove, W., MacDonald, K. Randomized phase 2 study of the oral histone deacetylase inhibitor CI-994 plus gemcitabine (Gem) vs placebo (PBO) plus Gem in second-line nonsmall cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002.
34. Sharma, S., White, D., Kris, M., **Otterson, G.**, Allen, J., Murren, J., Schiller, J., Sandler, A., Ryan, C., Ratain, M., Marirez, J., Imondi, A. A multicenter phase I clinical and pharmacologic study of inhaled doxorubicin (Resmycin) in adults with advanced solid tumors affecting the lungs. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002.
35. Villalona-Calero, M.A., **Otterson, G.**, Kanter, S., Young, D., Murgo, A., Fischer, B., Brooks, R., Straiko, M., Chen, D., Song, S., Zhang, Y., Chan, K., Grever, M.R., Wientjes, G., Au, J.L. A novel strategy to decrease taxane-resistance in non-small-cell lung cancer (NSCLC) patients. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002.
36. Ritch, P.S., Belt, R., George, S., Valdivieso, M., Figueroa, J., McCachren, S., Modiano, M., Miller, G.L., Leonardo, J., Dorr, A., Oliver, J., Holmlund, J., **Otterson, G.A.**, Villalona-Calero, M.A. Phase I/II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-

- small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002.
37. Hoffman, P.C., Winegarden, J.D., Mauer, A.M., Rudin, C.M., Villalona, M.A., Golomb, H.M., Sxeto, L.L., Vokes, E.E., Wade, J.L., **Otterson, G.A.** Phase II study of Oxaliplatin (OX) and paclitaxel (PA) in advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002.
  38. **Otterson, G.A.**, Lavelle, J., Villalona-Calero, M.A., Shah, M., Chan, K., Fischer, B., Grever, M. A phase I study of fenretinide combined with paclitaxel and cisplatin for the treatment of refractory solid tumors. 14<sup>th</sup> AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Frankfurt, Germany, 2002.
  39. Villalona-Calero, M.A., Duan, W., **Otterson, G.A.**, Kleiber, B., Hindman, K., Shah, M., Young, D., Wu, W., Kuhn, J. Thalidomide modulation of Irinotecan; and NF- $\kappa$ B dependent effect? 14<sup>th</sup> AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Frankfurt, Germany, 2002.
  40. Villalona-Calero, M.A., Monk, P., Waite, R., Guttridge, D., Kuhn, J., **Otterson, G.A.**, Hauger, M., Rhoades, C., Young, D., Caligiuri, M. Tumor necrosis alpha (TNF $\alpha$ ) blockade as an adjunct to dose intense chemotherapy. 14<sup>th</sup> AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Frankfurt, Germany, 2002.
  41. Duan, W., Gao, L., Zhu, S.-G., Jin, D., **Otterson, G.A.**, Villalona-Calero, M.A. *In vivo* analysis of the influence of mutant p53 (273H) in proliferating cell nuclear antigen (PCNA) and p21<sup>WAF1/CIP1</sup> expression in transgenic mice. The 5<sup>th</sup> Annual Ohio State University Comprehensive Cancer Center Scientific Retreat, Dublin, OH, 2003.
  42. Duan, W., Gao, L., Zhu, W.-G., **Otterson, G.A.**, Villalona-Calero, M.A. *In vivo* expression of human mutant p53-273H does not regulate the expression of p21WAF1/CIP1 in p53 null and heterozygous mice. American Association for Cancer Research, Washington, D.C. 2003.
  43. Zhu, W.-G., Duan, W., Villalona-Calero, M.A., **Otterson, G.A.** Cytotoxicity of 5-aza-2'-deoxycytidine by induction of a DNA damage response pathway. American Association for Cancer Research, Washington, D.C. 2003.
  44. Kindwall-Keller, T.L., **Otterson, G.A.**, Young, D., Rhoades, C.A., Stanek, M.J., Neki, A.S., Criswell, T.S., Soong, R., Diasio, R.B., Villalona-Calero, M.A. Phase II evaluation of docetaxel and capecitabine in previously treated non-small cell lung cancer patients. Proceedings of the American Society of Clinical Oncology, Chicago, IL 2003.
  45. **Otterson, G.A.**, Herndon, J., Watson, J., Terrenoire, J., Green, M.R., Kindler, H.L. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and



- Leukemia Group B (CALGB 39807). Proceedings of the American Society of Clinical Oncology, Chicago, IL 2003.
46. Grainger, A.V., Browning, K.K., Wewers, M.E., Loughlin, H., Shapiro, C.L., Villalona-Calero, M.A., Ross, P., **Otterson, G.A.** Identifying cancer patients, family members, and a teachable moment for smoking cessation. Proceedings of the American Society of Clinical Oncology, Chicago, IL 2003.
  47. Murren, J.R., White, D.D., Rizvi, N., Kris, M., Schiller, J., Sandler, A., Ryan, C., Ratain, M., Pass, H.I., **Otterson, G.** Phase I and pharmacokinetic trial of inhalational doxorubicin (Resmycin™). Oral presentation at the 10<sup>th</sup> World Conference on Lung Cancer, Vancouver, BC Lung Cancer 2003, Vol 41, Suppl 2, pg 44.
  48. Villalona-Calero, M.A., **Otterson, G.**, Wientjes, G., Murgo, A., Jensen, R., Yeh, T., Chen, D., Song, S., Grever, M., Au, J. Phase II evaluation of low dose Suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patients. 10<sup>th</sup> World Conference on Lung Cancer, Vancouver, BC Lung Cancer 2003, Vol 41, Suppl 2, pg 149.
  49. Villalona-Calero, M., Kindwall-Keller, T., Soong, R., Daisio, R., Nuovo, G., **Otterson, G.**, Criswell, T., Neki, A., Rhoades, C. Phase II study of docetaxel in combination with capecitabine in patients with previously treated non-small cell lung cancer (NSCLC). 10<sup>th</sup> World Conference on Lung Cancer, Vancouver, BC Lung Cancer 2003, Vol 41, Suppl 2, pg 144.
  50. Mauer, A.M., **Otterson, G.A.**, Winegarden, J.D., Rudin, C.M., Villalona, M.A., Szeto, L., Hoffman, P.C., Vokes, E.E. Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer. 10<sup>th</sup> World Conference on Lung Cancer, Vancouver, BC Lung Cancer 2003, Vol 41, Suppl 2, pg 226.
  51. Bekaii-Saab, T.S., Lavelle, J.W., Grainger, A.V., Rothrauff, S., Villalona-Calero, M.A., **Otterson, G.A.**, Ross, P. Photodynamic therapy (PDT) can be incorporated into the multimodality treatment of loco-regionally advanced non-small cell lung cancer (NSCLC) with obstructive lesions. Oral presentation at the 10<sup>th</sup> World Conference on Lung Cancer, Vancouver, BC Lung Cancer 2003, Vol 41, Suppl 2, pg 90.
  52. Photodynamic therapy (PDT) for primary tracheal carcinoma. 10<sup>th</sup> World Conference on Lung Cancer, Vancouver, BC Lung Cancer 2003, Vol 41, Suppl 2, pg 266.
  53. Duan, W., Li, G., Druhan, L.J., Zhu, W.-G., **Otterson, G.A.**, Villalona-Calero, M.A. Pirh2, a newly identified ubiquitin protein ligase, is overexpressed in lung cancer. The 6<sup>th</sup> Annual Ohio State University Comprehensive Cancer Center Scientific Retreat, Dublin, OH, 2004.
  54. Villalona-Calero, M.A., **Otterson, G.A.**, Wientjes, G., Kobayashi, K., Jensen, R., Young, D., Yeh, T., Song, S., Grever, M., Au, J. Phase II study of low dose

suramin as a sensitizer of paclitaxel/carboplatin in non small cell lung cancer. Proceedings of the American Society of Clinical Oncology, New Orleans, LA, 2004.

55. **Otterson, G.A.**, Villalona-Calero, M.A., Grainger, A., Hicks, W., Murren, J., Ellerton, J., Mojzisek, C., Gerber, M., Westaway, D. Preliminary results of a phase I/II study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer. 16<sup>th</sup> EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland, 2004.
56. Monk, J.P., Villalona-Calero, M.A., Dupont, J., Larkin, J., **Otterson, G.**, Spriggs, D., Hannah, A.L., Cropp, G.F., Johnson, R.G., Hensley, M.L. Phase I trial of KOS-862 (epothilone D) in combination with carboplatin in patients with solid tumors. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2005.
57. Olencki, T., Wientjes, G., **Otterson, G.**, Saab, T., Grainger, A., Yeh, T., Jensen, R., Young, D., Au, J., Villalona-Calero, M.A. Modulation of chemotherapy resistance with low dose suramin in refractory non-small cell lung cancer patients: a phase I study of sequential non-cross resistant chemotherapy. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2005.
58. Boccia, R., Liu, D., Silberstein, P., Tchekmedyian, N.S., Holladay, C., Tomita, D., Rossi, G., **Otterson, G.** Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2005.
59. **Otterson, G.A.**, Villalona-Calero, M.A., Grainger, A., Hicks, W., Murren, J., Schiller, J., Gerber, M., Ellerton, J. Results of a phase I study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2005.
60. Klamerus, J.F., Burke, E., Leier, C.V., **Otterson, G.A.** Bronchogenic carcinoma following cardiac transplantation. Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2005.
61. Bekaii-Saab, T.S., Grainger, A.V., Lavelle, J.W., Rothrauff, S., Ross, P., **Otterson, G.A.** Villalona-Calero, M., Duan, W., Gao, L., Zhang, L., Wu, X., **Otterson, G.** Establishment and characterization of a line of transgenic mice harboring a lung specific human type II p53 (175H) mutation; a potential model of human disease. 11<sup>th</sup> World Conference on Lung Cancer, Barcelona, Spain, 2005.
62. Klamerus, J., Burke, E., Leier, C., **Otterson, G.** Bronchogenic carcinoma after cardiac transplantation. 11<sup>th</sup> World Conference on Lung Cancer, Barcelona, Spain, 2005.
63. Pleister, A., Fisher, J., **Otterson, G.** Retrospective analysis of octogenarians with lung cancer. 11<sup>th</sup> World Conference on Lung Cancer, Barcelona, Spain, 2005.

64. Kosuri, K., **Otterson, G.**, Villalona-Calero, M., Murren, J., Gerber, M., Ellerton, J. Phase I study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer. 11<sup>th</sup> World Conference on Lung Cancer, Barcelona, Spain, 2005.
65. Kosuri, K., Wu, X., **Otterson, G.A.** Epigenetics of Mesothelioma. 2<sup>nd</sup> Conference of the Mesothelioma Applied Research Foundation, Las Vegas, NV, 2005.
66. Silberstein, P., Boccia, R., Liu, D., Tchekmedyan, S., Holladay, C., Tomita, D., Rossi, G., **Otterson, G.A.** Synchronicity: evaluating darbepoietin alfa administered at 300 mcg every three weeks to treat chemotherapy induced anemia in breast cancer patients. San Antonio Breast Cancer Symposium, San Antonio, TX, 2005.
67. **Otterson, G.A.**, Villalona-Calero, M.A., Ellerton, J.A., Westaway, D., Gerber, M., Murren, J., Phase I/II study of inhaled doxorubicin combined with platinum based therapy for advanced NSCLC. 4<sup>th</sup> International Chicago Symposium on Malignancies of the Chest and Head & Neck, Chicago, IL, J Thoracic Oncol 1(8), October 2006.
68. Villalona-Calero, M.A., Duan, W., Li, G., Wu, X., **Otterson, G.** Establishment of lung cancer transgenic animal models with type-specific p53 mutants for experimental therapeutic studies. 4<sup>th</sup> International Chicago Symposium on Malignancies of the Chest and Head & Neck, Chicago, IL, J Thoracic Oncol 1(8), October 2006.
69. Smith, L.T., Lin, M., Brena, R.M., Lang, J.C., Schuller, D.E., **Otterson, G.A.**, Morrison, C.D., Smiraglia, D.J., Plass, C. Regulation of cancer growth in HNSCC and NSCLC conferred by TCF21. 4<sup>th</sup> International Chicago Symposium on Malignancies of the Chest and Head & Neck, Chicago, IL, J Thoracic Oncol 1(8), October 2006.
70. Crawford J, Burris H, Stephenson J, **Otterson G**, Stein M, McGreivy J, Sun Y, Ingram M, Yang L, Schwartzberg LS. Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2007.
71. Arce-Lara CE, Cataland S, Brady C, Kraut E, **Otterson G**, Villalona-Calero M, Bekaii-Saab T. A single center review of the experience with mitomycin C (MMC) and the risk of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS). Proceedings of the American Society of Clinical Oncology, Chicago IL, 2007.
72. Ort EM, Confer P, **Otterson GA**. Retrospective review of pulmonary neuroendocrine/carcinoid tumors at Ohio State University. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2007.
73. Karpenko MJ, Liu A, Aimuwu J, Wang L, Wu X, Villalona-Calero MA, Young D, Chan K, Grever MR, **Otterson GA**. Phase I study of 5-aza-2'-deoxycytidine in

combination with valproic acid in patients with NSCLC. Oral Presentation. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2008.

74. **Otterson GA**, Wang L, Wu X, Duan W, Gao L, Karpenko MJ, Villalona-Calero MA. Effect of dichloroacetate in combination with chemotherapy on human lung cancer cells. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2008.
75. Lustberg MB, Bekaii-Saab TS, Diasio R, Ezzeldin H, Starrett SL, **Otterson GA**, Villalona MA. Phase II and pharmacogenetic study of docetaxel and capecitabine in chemo-naïve non-small cell lung cancer patients. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2008.
76. Herbst RS, Stern H, Amler L, **Otterson G**, Lin M, O'Connor P, Hainsworth J. Biomarker evaluation in the phase III, placebo controlled, randomized BeTa trial of bevacizumab and erlotinib for patients with advanced non-small cell lung cancer after failure of standard 1<sup>st</sup>-line chemotherapy: correlation with treatment outcomes. J Thorac Oncol 4;9:S323. September 2009.
77. Edelman MJ, **Otterson GA**, Leach J, Malpass T, Salgia R, Jones D, Szakacs N, Govindan R. Multicenter phase II trial of motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol 4;9:S455. September 2009.
78. Miller AA, Pang H, Hodgson L, Ramnath N, **Otterson GA**, Vokes EE. A phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer: CALGB 30602. J Thorac Oncol 4;9:S816. September 2009.
79. Leon ME, Villalona-Calero MA, **Otterson GA**, Zhao W. Epidermal growth factor receptor (EGFR) mutations, KRAS mutations and EGFR gene amplification by FISH on cytology specimens. US and Canadian Academy of Pathology (USCAP) 99<sup>th</sup> Annual Meeting, Washington DC, March 23, 2010. (Platform presentation)
80. Bertino EM, **Otterson GA**, Villalona-Calero MA, Nana-Sinkam SP, Ghany AM, Donthireddy KR, Abdel Karim NFM, Cantrell S, Phillips GS. Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2010.
81. Lam ET, **Otterson GA**, Donthireddy KR, Thurmond J, Hade E, Coffey MC, Villalona-Calero MA. Phase II study of reovirus with paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer who have Kras or EGFR-activated tumors. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2010.
82. Mortazavi A, Deam D, Ling Y, Harper EJ, Phelps MA, Espinoza-Delgado IJ, Monk III JP, **Otterson GA**, Grever MR, Bekaii-Saab T. A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients

- with advanced solid tumors. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2010.
83. Zornosa C, Mamet R, Reid ME, Ettinger DS, **Otterson GA**, Rabin MS, Hayman J, Niland JC, Pisters K. Utilization of adjuvant therapy among completely resected non-small cell lung cancer patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2010.
  84. Dudek A, Pang H, Kratzke RA, **Otterson GA**, Vokes EE, Kindler HL. CALGB 30601: a phase II study of dasatinib in patients with previously treated malignant mesothelioma. Proceedings of the American Society of Clinical Oncology, Chicago IL, June 2010.
  85. Villalona-Calero MA, Stinchcombe T, Phelps MA, Starrett SL, Papp AC, Ghany AM, Hicks WJ, **Otterson GA**, Socinski MA, Zhao W. Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans with NSCLC. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2010.
  86. Vendergrift JL, Mamet R, Zornosa C, Reid ME, Rabin MS, Ettinger DS, Kalemkerian GP, **Otterson GA**, Niland JC, Pisters K. First-line systemic therapy in metastatic non-small cell lung cancer patients treated at National Comprehensive Cancer Network (NCCN) institutions: an analysis from the NCCN Oncology Outcomes Database Project. Proceedings of the American Society of Clinical Oncology, Chicago IL, 2010.
  87. Ferketich A, **Otterson G**, King M, Browning K, Wewers M. A pilot study to examine the feasibility of delivering a tobacco dependence treatment program at the time of lung cancer screening. J Thorac Oncol 5;12:S549. December 2010.
  88. Bertino EM, Zhao W, Villalona-Calero M, **Otterson GA**. EML4-ALK translocation in lung cancer: an institutional clinical experience. . J Thorac Oncol 5;12:S532. December 2010.
  89. Ferketich AK, Niland JC, Mamet R, Zornosa C, D'Amico TA, Ettinger DS, Kalemkerian GP, Pisters KM, Reid ME, **Otterson GA**. Survival among smokers and nonsmokers in the National Comprehensive Cancer Network (NCCN) non-small cell lung cancer (NSCLC) cohort. . J Thorac Oncol 5;12:S513. December 2010.
  90. Lepisto EM, Vandergrift JL, Kalemkerian GP, Pisters KM, Zornosa C, Rabin MS, Reid ME, Koczywas M, **Otterson GA**, Ettinger DS. Oncology medication utilization based on federal drug administration (FDA) labeling, national comprehensive cancer network (NCCN) clinical practice guideline (GL) recommendations, and evidence for patients with advanced non small cell lung cancer (NSCLC): An analysis from the NCCN Oncology Outcomes Database. Proceedings of the International Society for Pharmacoeconomics and Outcomes Research Meeting, Baltimore, MD, May 21-25, 2011.

91. Bertino EM, **Otterson GA**, Villalona-Calero MA, Nana-Sinkam SP, Ghany AM, Donthireddy KR, Abdel Karim NFm, Cantrell S, Phillips GS. Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies. Proceedings of the 14<sup>th</sup> World Conference on Lung Cancer, IASLC – International Association for the Study of Lung Cancer, Amsterdam, The Netherlands, July 3 – 7, 2011.
92. Gao L, Duan W, Wu X, Chen A, **Otterson GA**, Villalona MA. Compensatory activation of alternative DNA repair pathways following exposure to the PARP Inhibitor ABT-888 *in vitro* and in patients with solid malignancies. AACR Annual Meeting, March 31 – April 4, 2012, Chicago, IL. Abstract # 4682
93. Wu X, Yan F, Duan W, Zhang J, Gao L, Crawford M, Villalona MA, Nana-Sinkam P, **Otterson GA**. Global miRNA expression changes induced by HDAC-42 and 5-azaCdr in lung cancer cells. AACR Annual Meeting, March 31 – April 4, 2012, Chicago, IL. Abstract # 4082
94. Bertino EM, Villalona MA, Nana-Sinkam P, Cantrel S, Rahmani C, Symmes C, Phillips GS, **Otterson GA**. Phase 2 Trial of *nab*-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies. AACR Annual Meeting, March 31 – April 4, 2012, Chicago, IL. Abstract # LB-225
95. Duan W, Gao L, Brooks C, Kalvala A, Wu X, **Otterson GA**, Villalona MA. Establishment of P53 mutant type specific spontaneous lung tumor in transgenic mice for treatment. AACR Annual Meeting, March 31 – April 4, 2012, Chicago, IL. Abstract # 4740
96. Ou S, Govindan R, Eaton K, **Otterson G**, Gutierrez M, Mita A, Argiris A, Brega N, Usari T, Tan W, Ho S, Robert F. Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced Non-Small Cell Lung Cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, Chicago, IL, June 2012
97. **Otterson G**, Riely GJ, Shaw A, Crino L, Kim DW, Martins R, Salgia R, Zhou C, Solomon B, Wilner K, Polli A, Tang Y, Bartlett C, Ou S. Clinical characteristics of ALK+NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): potential implications for management. Proceedings of the American Society of Clinical Oncology, Chicago, IL, June 2012
98. Luu D, D'Amico T, Kalemkerian G, Kocywas M, Mamet R, Niland J, Pisters K, Rabin M, Zornosa C, **Otterson G**. Retrospective analysis of the impact of age on overall survival in patients with Non-Small Cell Lung Cancer. Proceedings of the American Society of Clinical Oncology, Chicago, IL, June 2012
99. Villalona-Calero M, Lam E, **Otterson G**, Zhao J, Timmons M, Subramaniam D, Hade E, Gill G, Coffey M, Bertino E. Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors. Proceedings of the 24<sup>th</sup> EORTC-NCI-AACR Symposium on Molecular Target and Cancer Therapeutics, European Journal of Cancer, Volume 48, Suppl. 6, November 2012, abstr. 603

100. Kalvala A, Gao L, Barnwel B, **Otterson G**, Villalona Calero M, Duan W. Mutations in Rad51C in colon tumors. Proceedings of the 2013 AACR Annual Meeting, abstr 4221.
101. Gao L, Duan W, Barnwell B, Kalvala A, **Otterson G**, Villalona-Calero M. Sensitivity of small cell lung cancer cells with defective Fanconi Anemia (FA) pathway to BCL2 inhibitors. Proceedings of the 2013 AACR Annual Meeting, abstr 4365.
102. Duan W, Rees T, Vu K, Barnwell B, Gao L, Kalvala A, Wu X, **Otterson G**, Villalona-Calero M. Promoter hypermethylation and gene expression of FANCF in non-small cell lung cancer (NSCLC). Proceedings of the 2013 AACR Annual Meeting, abstr 4246.
103. Villalona-Calero M, Lam E, Zhao W, **Otterson G**, Subramaniam D, Chao B, Timmons M, Schaaf L, M Gill G, Coffey M. Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors. 15th World conference in lung cancer. P1.11-026, October 2013
104. Duan W, Gao L, Kalvala A, Brooks C, Barnwell B, Mo X, Ding H, Shilo K, **Otterson G**, and Villalona-Calero M. Type of P53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung specific transgenic mice. 15<sup>th</sup> World conference in lung cancer, October 2013
105. Bertino EM, Chu B, Ahn D, Villalona-Calero M, Chao B, Shields P, Hade E, **Otterson GA**, Carbone D. A Phase II study of single agent Selinexor (KPT-330) in separate cohorts of relapsed squamous and small cell lung cancer. IASLC 14<sup>th</sup> Annual Targeted Therapies for the Treatment of Lung Cancer. February 2014. Santa Monica, CA.
106. Chen W, Brodsky S, Zhao W, **Otterson G**, Villalona-Calero M, Satoskar A, Hasan A, Pelletier R, Ivanov I, Ross P, Nadasdy T and Shilo K. Y-Chromosome Status Identification Suggests a Recipient Origin of Post-Transplant Non-Small Cell Lung Carcinomas: Chromogenic in situ Hybridization Analysis. United States College of Pathology meeting. San Diego. March 2014
107. Kalvala A, Gao L, Barnwell B, **Otterson G**, Villalona-Calero M, and Wenrui Duan. Identification of a Novel Rad51c-ATXN7 fusion gene in colorectal tumors. 2014 AACR Annual Meeting, p2407
108. Gao L, Barnwell B, Kalvala A, **Otterson G**, Duan W and Villalona-Calero M. Combined BCL-2/XL and mTor Inhibition Promotes Apoptosis in Small Cell Lung Cancer. 2014 AACR Annual Meeting, p5434.
109. J. C. Grecula, S. Elias, K. Thelen, M. Knopp, **G. Otterson**, P. Ross, E. Kassis, M. Welliver, M. Villalona-Calero, K. Shilo, S. Lo, G. Jia, W. C. Yu, B. Yuh, S. Ghosh, E. Bertino, N. Mayr. Dynamic-Contrast Enhanced MR and Volume Regression rate as a preoperative predictive assay in patients with Non-Small Cell Lung Cancer,

2014 ASTRO meeting. 9/2014

110. Bertino E, McMichael E, Villalona-Calero M, Grever M, Carson W, **Otterson G**. Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with lenalidomide in advanced solid tumors: A phase 1 trial. 2014 ASCO Annual Meeting. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 3044).
111. Camidge D, Ou S, Shapiro G, **Otterson G**, Villaruz L, Villalona-Calero M, Iafrate A, Varella-Garcia M, Dacic S, Cardarella S, Zhao W, Tye L, Stephenson P, Wilner K, James L, Socinski M. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 8001)
112. Chu B, Ozkan E, Erdal S, Zhao W, Shilo K, **Otterson G**. Computed tomography (CT) imaging features in early-stage lung adenocarcinoma differentiating exon 19 and exon 21 epidermal growth factor receptor (EGFR) mutated tumors. 2014 ASCO Annual Meeting. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 7548).
113. Bertino EM, Williams TM, Nana-Sinkam P, Shilo K, Chatterjee M, Mo X, Cantrell S, Rahmani M, Symmes C, Phillips GS, Villalona-Calero M, **Otterson GA**. Phase II Trial of *nab*-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies. 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, October 30.
114. Duan W, Gao L, Aguila B, Dotts K, Kalvala A, Webb A, Papp A, Sadee W, **Otterson GA**, Villalona-Calero. Genetic alterations in the Fanconi Anemia pathway in lung and colorectal cancers. *4th Global Cancer Genomics Consortium Symposium, Kyoto, Japan.* Page 18, 11/2014
115. Kalvala A, Gao L, Dotts K, Cortes OC, Barnwel B, **Otterson G**, Villalona Calero MA, Duan W. Potential oncogenic function of Rad51C splice variant in colorectal tumors. *Proceedings of the 106 Annual Meeting of the American Association for Cancer Research*, 2015 (abstr 3866). 04/2015
116. Gao L, Duan W, Dotts K, Kalvala A, Aguila B, **Otterson G**, Villalona-Calero MA. Inhibition of pro-survival pathways in lung cancer cells with functional defects in the Fanconi Anemia pathway. *Proceedings of the 106 Annual Meeting of the American Association for Cancer Research*, 2015 (abstr 559). 04/2015
117. Duan W, Gao L, Dotts K, Kalvala A, Aguila B, **Otterson GA**, Villalona-Calero. Genetic alterations in the Fanconi Anemia pathway in lung cancers. 17th World Conference on Lung Cancer (WCLC 2015). September 9, 2015. Denver, CO, USA. *J Thorac Oncol.* 10(9) Suppl 2):S391, 2015
118. Fink A, Kalvala A, Gao L, Dotts K, Aguila B, Tang S, **Otterson GA**, Villalona MA, Duan W. Promoter hypermethylation status of Fanconi Anemia (FA) pathway genes FANCF, FANCL and FANCS in non-small cell lung cancer (NSCLC). In: *Proceedings of the 107th Annual Meeting of the American Association for Cancer*



Research; 2016 Apr 16-20; New Orleans, Louisiana. Abstract # 4438

## Oral Presentations

### Invited Lectures – National/International:

1. Roswell Park Cancer Institute, Department of Medicine Lecture: RB and friends – implications for lung cancer. March 15, 1994.
2. University of Iowa Cancer Center Lecture: The retinoblastoma protein and related gene products. May 3, 1994.
3. Stanford University Cancer Center Lecture: The retinoblastoma protein and related gene products. May 24, 1994.
4. American Association for Cancer Research, Toronto, Canada, Minisymposium: Absence of p16<sup>INK4</sup> protein is restricted to the subset of lung cancer lines that retain wildtype RB. April, 1995.
5. Comprehensive Management of Lung Cancer, Columbus, OH, Biology and genetics of lung cancer, June 12, 1999.
6. 6<sup>th</sup> International Association for the Study of Lung Cancer Lung Biology Workshop, Aspen, CO, Methylation changes in lung cancer, August 8-11, 1999.
7. Ohio Medical Education Network (OMEN), Columbus, OH, New strategies in the treatment of lung cancer, November 9-12, 1999.
8. Cancer and Leukemia Group B, Spring Core Meeting, Chicago, IL, Methylation profiles of resected NSCLC, March 2, 2002.
9. Global Lilly Oncology Young Investigators' Meeting, Indianapolis, IN, Phase II trial of Affinitac antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-small cell lung cancer. June 20, 2002.
10. 2<sup>nd</sup> International Congress on Monoclonal Antibodies in Cancer, Banff, Alberta, CA, Anti-TNF approaches in oncology, September 1, 2002.
11. 7<sup>th</sup> World Congress on Advances in Oncology and the 5<sup>th</sup> International Symposium on Molecular Medicine, Hersonissos, Crete, Greece, Alterations of DNA methylation and histone acetylation in cancer, October 11, 2002.
12. Ohio Medical Education Network (OMEN), Columbus, OH, New strategies in the treatment of lung cancer, November 8, 2002.

13. Workshop on clinical translation of gene-re-expression in cancer and working group meeting on clinical development of HDAC inhibitors and demethylating agents, sponsored by Johns Hopkins University School of Medicine and Cancer Therapy Evaluation Program, National Cancer Institute, January 17-18, 2003.
14. Medical College of Wisconsin, Division of Hematology/Oncology Lecture: Lung cancer: how do we improve survival? February 21, 2003.
15. Central Baptist Research Group, Lexington, KY, Strategies to improve the survival from lung cancer, March 20, 2003.
16. Roswell Park Cancer Institute, Department of Pharmacology, Buffalo, NY, Manipulating Epigenetics for Cancer Therapy, January 12, 2004.
17. 1<sup>st</sup> Aerosol Delivery for Cancer Therapy Workshop, Albuquerque, NM, Clinical experience with inhalational doxorubicin, April 16, 2004.
18. School of Basic Medical Sciences, Peking University, Beijing, China, Manipulating Epigenetics for Cancer Therapy, May 25, 2005.
19. Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China, Manipulating Epigenetics for Cancer Therapy, May 30, 2005.
20. Zhong Shang Hospital, Fudan University, Shanghai, China, Innovative Therapies for Lung Cancer, May 30, 2005.
21. NCCN Clinical Practice Guidelines in Oncology Symposium: Non-Small Cell Lung Cancer; Management of Metastatic Non-Small Cell Lung Cancer, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL November 11, 2005.
22. Metro Health Medical Center, Cleveland, OH, Medical Grand Rounds: Recent Advances with HER1/EGFR – Targeting Therapies for Non-Small Cell Lung Cancer. February 9, 2006.
23. The Fifth Jordan Oncology Society Conference, Amman, Jordan, Lung Cancer in the New Millenium. April 13, 2006.
24. NCCN Clinical Practice Guidelines in Oncology Symposium: Non-Small Cell Lung Cancer; Management of Metastatic Non-Small Cell Lung Cancer, Fred Hutchinson Cancer Research Center, Seattle, WA June 16, 2006.
25. NCCN Clinical Practice Guidelines in Oncology Symposium: Non-Small Cell Lung Cancer; Workup, Prognostic Factors, and Markers, University of California San Francisco, San Francisco, CA September 11, 2006.
26. Novel Therapies in Thoracic Oncology: Inhalational Chemotherapy for Lung Cancer, University of Minnesota Medical School, Minneapolis, MN November 10, 2006.

27. Treatment of Metastatic NSCLC; MedNet21, Ohio State University Center for Continuing Medical Education, Columbus, OH December 15, 2006.
28. American Society of Clinical Oncology, 43<sup>rd</sup> Annual Meeting, Training Directors Special Session: Protecting the Educational Environment, Chicago, IL June 3, 2007.
29. Annenberg Center for Health Sciences CME Lecture, Personalizing Therapy in NSCLC, Louisville, KY September 24, 2009.
30. NCCN Innovative Diagnostics & Therapeutics in Cancer Care; Diagnostic, Prognostic and Predictive Markers in the Management of NSCLC, New York, NY October 2, 2009.
31. NSCLC Experts in Residence Speaker Series, "NSCLC: Toward Personalized Therapy" Southern Ohio Medical Center, Portsmouth, OH, January 14, 2011.
32. NSCLC Experts in Residence Speaker Series, "NSCLC: Toward Personalized Therapy" Saint Anthony Medical Center, Guilford Square, Rockford, IL, February 17, 2011.
33. NSCLC Experts in Residence Speaker Series, "NSCLC: Toward Personalized Therapy" James Graham Brown Cancer Center, University of Louisville, Louisville, KY, February 26, 2011.
34. NCCN Abraxane Investigators Meeting, "Phase II Trial of Abraxane plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding from VEGF Directed Therapies", The Westin Diplomat, Hollywood, FL, March 11, 2011.
35. NAMCP Spring Managed Care Forum, "Optimizing Treatment Strategies in the Management of Non Small Cell Lung Cancer", Gaylord Palms Resort and Convention Center, Orlando, FL April 14, 2011.
36. NSCLC Experts in Residence Speaker Series, "NSCLC: Toward Personalized Therapy" Mercy Medical Center, Springfield, MA, June 15, 2011.
37. 2011 NCCN Congress: Respiratory Tract Cancers™, "Adjuvant Therapy of Non-Small Cell Lung Cancer" Searle Center, Durham, North Carolina, June 29, 2011.
38. 2011 GLICO Latin American Oncology Conference Personalized Medicine and Challenges in Clinical Research, "Lung Cancer Guidelines: How to incorporate molecular patient selection in routine clinical practice" Hotel Sofitel, Rio De Janeiro, July 9, 2011.
39. NSCLC Experts in Residence Speaker Series, "NSCLC: Toward Personalized Therapy" Macon, GA, August 18, 2011.
40. NSCLC Community Oncology Meeting, Grand Rounds at Tunnell Cancer Center, Rehoboth Beach, DE, February 29, 2012

41. 2012 NCCN Fellows Recognition Program: New Horizons in Quality Cancer Care, Hollywood, FL, March 14, 2012
42. American Cancer Center Society Reception, Columbus, OH, March 22, 2012
43. NSCLC Lecture, Workshop with the Experts, VA NJ Health Care Systems, East Orange Campus. East Orange, NJ. April 24, 2012
44. NSCLC Meeting Series: Ensuring Personalization of Care Across the Continuum of Disease and Treatment Settings: Best Practices in the Management of Advanced NSCLC. Defiance, OH. May 31, 2012
45. NSCLC Community Oncology Meeting. Critical Issues in Optimal Treatment, Emerging Research and Novel Therapeutics. Billings, MT. June 5, 2012.
46. NSCLC Meeting Series: Ensuring Personalization of Care across the Continuum of Disease and Treatment Settings: Best Practices in the Management of Advanced NSCLC. Midlakes Clinic, Round Lake Beach, IL. August 2, 2012
47. Sunday Brunch with the Experts - Non-Small Cell Lung Cancer: Advances in Screening, Treatment and Survivorship. NCCN 18th Annual Conference. Hollywood, FL March 16, 2013
48. Advanced NSCLC VA Program. Advanced Non-Small Cell Lung Cancer: Optimizing the Care of Veterans. W.G. (Bill) Hefner VA Medical Center, Salisbury, NC. April 18, 2013
49. Advanced NSCLC VA Program. Advanced Non-Small Cell Lung Cancer: Optimizing the Care of Veterans. Beckley VA Medical Center, Beckley, WV. May 24, 2013
50. Compliance with NCCN Guidelines in the Care of Lung Cancer Patients. Presenter. Elkhart General Hospital. Elkhart, IN. June 26, 2013.
51. Grand Rounds. Mutation Testing in Solid Tumors Directing Therapy. Med Central Hospital, Mansfield, OH. April 15, 2014.
52. NCCN NSCLC Webinar Series - Discuss the optimal evaluation and workup of patients with NSCLC. March 25, 2014.
53. NCCN NSCLC Webinar Series - Describe the appropriate selection of therapies for patients with NSCLC using biomarker data. April 1, 2014
54. 2014 NCCN Congress Series: Utilizing Guidelines to Customize Patient Care in Non-Small Cell Lung Cancer. Biomarkers and Testing in Lung Cancer, October 25, 2014, Boston, MA.

Lectures - The Ohio State University:

1. Department of Internal Medicine, Grand Rounds, Lung Cancer – Where do we go from here? August 9, 2001
2. The 5<sup>th</sup> Annual Comprehensive Cancer Center Scientific Meeting, The Ohio State University CCC, Clinical aspects of methylation in lung cancer, April 25, 2003.
3. Research Staff Lecture, The Ohio State University CCC, Hypermethylation of promoter regions and its relationship to cancer, May 27, 2003.
4. Division of Hematology/Oncology, ASCO Lung Cancer Update, June 10, 2003.
5. Department of Pathology Grand Rounds: Novel Therapies in Lung Cancer, Clinco-Pathologic Linkage, March 8, 2006.
6. The 9<sup>th</sup> Annual Comprehensive Cancer Center Scientific Meeting: Environment and Cancer: a Transdisciplinary Approach. The Ohio State University CCC, Review of molecular differences between smoking related and non-smoking related lung cancer, February 23, 2007.
7. Ohio State University Center for Continuing Medical Education, 21<sup>st</sup> Century Care for Lung Cancer, Course organizer and speaker, Inhalational therapies for lung cancer, March 2-3, 2007.
8. OSU Comprehensive Cancer Center, Experimental Therapeutics Retreat, Lung Cancer at OSU, June 12, 2007.
9. OSU Comprehensive Cancer Center, ASCO/ASH/AACR Review, Lung Cancer, June 16, 2007.
10. OSU 1<sup>st</sup> Comprehensive Spine and Bone Tumor Symposium, Multimodality Treatment of Loco-Regional NSCLC, May 3, 2008.
11. OSU Comprehensive Cancer Center, Oncology Review 2008, Lung Cancer, June 21, 2008.
12. Ohio State University Center for Continuing Medical Education, Lung Cancer Update, Course organizer and speaker, Biomarker Directed Therapy, April 3, 2009.
13. OSU Department of Internal Medicine, Resident's Board Review: High Yield Solid Tumor for Internal Medicine, April 9, 2009.
14. 2009 Oncology Update: Current and New Horizons, Thoracic Oncology: Strategies for Systemic Therapy, October 30, 2009.
15. 2009 Lung Cancer Awareness Month, JamesCare for Life, November 19, 2009.
16. "Treatment of Metastatic NSCLC". MedNet21, Ohio State University Center for Continuing Medical Education, Columbus, OH January 21, 2011.

17. "Paraneoplastic Syndromes". Invited Speaker for Palliative Care Grand Rounds. The Ohio State University Center for Palliative Care, Hospice and Palliative Medicine Program, Graves Hall, Columbus, OH, March 2, 2011.
18. "Thoracic Disease Site Committee Report", Invited Speaker for MSAC Meeting. The James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, April 8, 2011.
19. JamesCare for Life, Invited Speaker for The Annual Lung Cancer Conference, "What is new in lung cancer 2011?" November 3, 2011.
20. Department of Internal Medicine, Council of Chief Fellows Lecture, "What to do/not do on your interview day" Biomedical Research Tower, Columbus, OH November 10, 2011.
21. "OSU 10112 Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity with lenalidomide in advanced solid tumors", Phase I/II Meeting, Starling Loving Hall, Columbus, OH December 7, 2011.
22. Greene OSU May 2013 Scholarship Awards, Greene County Alumni Club, Fairborn, OH. May 23, 2013.
23. Department of Radiology, Didactics Lecture, "Principles of Chemotherapy". Room D200, Ohio State University, July 17, 2015.
24. Ohio State's 2016 ASCO Review, Lung Cancer Update. Hilton Columbus at Easton. June, 18, 2016.

Lectures - Local-Central Ohio:

1. Ohio-West Virginia Oncology Association, Sandusky, OH, Novel approaches to lung cancer, August 28, 1999.
2. Tumor Board, Kettering Hospital, Dayton, OH, Novel Strategies For Lung Cancer Treatment, April 16, 2000.
3. Tumor Board, Marietta Memorial Hospital, Marietta, OH, Treatment Options for Lung Cancer, November 7, 2000.
4. The Wellness Community, Columbus OH, Lung Cancer: Smoking, Genetics and Medical Treatment, November 11, 2000.
5. Springfield Community Hospital, Springfield, OH, Lung Cancer; current status and strategies for improvement, January 16, 2002.
6. Genesis-Bethesda Health Care System, Zanesville, OH, Lung Cancer; how do we improve survival? May 2, 2002.

7. The Wellness Community, Columbus, OH, Frankly Speaking About Lung Cancer: What You Need to Know About Lung Cancer & Its Treatment, December 5, 2002
8. American Cancer Society Volunteer Recognition Dinner, Columbus, OH, Lung Cancer: Future Research Promise, September 18, 2003.
9. Cleveland Ohio, Early Stage Lung Cancer: Adjuvant Chemotherapy. October 23, 2003.
10. Dayton, Ohio, Early Stage Lung Cancer: Adjuvant Chemotherapy. December 3, 2003.
11. Bridgesite Clinical Trials Summit, Columbus, Ohio, Lung Cancer: Adjuvant Chemotherapy. February 18, 2004.
12. Advanced Clinical Training in Oncology: Annenberg Center for Health Sciences, Columbus, Ohio, Lung Cancer; Etiology and Non-Small Cell Lung Cancer, May 27, 2004.
13. Advanced Clinical Training in Oncology: Annenberg Center for Health Sciences, Columbus, Ohio, Small Cell Lung Cancer, May 27, 2004.
14. Advanced Clinical Training in Oncology: Annenberg Center for Health Sciences, Columbus, Ohio, Case Presentations in Lung Cancer, May 27, 2004.
15. Pharmacy Seminar Series in Hematology/Oncology: Lung Cancer, Columbus, Ohio, August 23, 2004.
16. Mary Rutan Hospital Medical Staff Meeting: Lung Cancer Screening, Bellefontaine, Ohio, September 13, 2004.
17. The Wellness Community, Columbus, OH, Frankly Speaking About Lung Cancer: What You Need to Know About Lung Cancer & Its Treatment, November 10, 2004.
18. Cancer Care Across the Continuum: New Discoveries, New Modalities, Nursing CME Course, Columbus, OH, Multimodality Approach to the Treatment of Lung Cancer, February 25, 2005.
19. Pulmonary and Critical Care Medicine Update, 2005, Columbus, OH, New Developments in Lung Cancer Chemotherapy, March 5, 2005.
20. OSU ASCO GI Symposium Update, Moderator, April 7, 2005.
21. Family Practice Board Preparation Course, Columbus, OH, Hematology/Oncology, May 31, 2005, June 27, 2006, June 20, 2007, June 21, 2008.
22. The Wellness Community, Columbus, OH, Frankly Speaking About Lung Cancer: What You Need to Know About Lung Cancer & Its Treatment, November 1, 2005.

23. Gastrointestinal Cancers 2006: Current Updates on State of the Art Management. OSU GI CME Symposium, Moderator, September 30, 2006.
24. Lung Cancer 2007. Blanchard Valley Hospital Grand Rounds, January 19, 2007.
25. Lung Cancer in the Non (Never) Smoker. Ohio Department of Health, Environmental Protection Agency Area 5 Radon Meeting, April 11, 2008.
26. NCCN 2012 Congress: Lung Cancer. Adjuvant Therapy of Non-Small Cell Lung Cancer. Moderator. Columbus, OH. May 24, 2012
27. Genomic Precision Medicine Tumor Board – The Christ Hospital, July 29, 2015.
28. Wilson Memorial Respiratory Therapy Conference – October 1, 2015
29. Targeted Therapy for Lung Cancer. The 19<sup>th</sup> Annual Lewis A. Schmidt, MD, Memorial Cancer Symposium, Holzer Health Systems, Gallipolis, OH. October 31, 2015

## **Media**

1. NCCN 20<sup>th</sup> Annual Conference Advancing the Standard of Care. ASCO Post Newsreels – Adjuvant Therapy and Immunotherapy for Lung Cancer. March 13, 2015.
2. Delaware Gazette Article, Stacy Kess – Interviewer, Next Generation Genome Sequencing for Lung Cancer Tumors. November 14, 2013.
3. NBC4, Next Generation Sequencing for Lung Cancer, Columbus, OH. November 13, 2013.
4. WOSU-FM, All Sides with Ann Fischer Wellness Wednesday, Next Generation Lung
5. Cancer Sequencing Technology, Columbus, OH. September 25, 2013
6. WOSU radio call-in show, Fred Anderle, Open Line: Lung Cancer. November 9, 2004.

## **Community Activities**

- |           |  |
|-----------|--|
| 6/18/2011 | Emcee, The Grove City Relay For Life Survivor Dinner, Grove City Nazarene Church, Grove City, OH     |
| 6/18/2011 | Emcee, The Pickerington Relay For Life Survivor Luncheon, Pickerington High School, Pickerington, OH |



- 2005-2009 Watterson Band Boosters, (President 2008-09), Bishop Watterson High School, Columbus OH
- 2005-2010 Boy Scouts of America, Troop 298, Simon Kenton Council, Committee Member
- 2001 -2005 School Board, (President 2003-2004), St. Agatha's Primary School, Upper Arlington, OH
- 1981-1982 Assistant Manager, House of Charity, Spokane, WA
- 1977-1978 Senior Citizen's Center, Omaha, NE